



MEDICAL SCIENCE & DISCOVERY



ISSN: 2148-6832

Publisher LuLu Press, USA

International Journal of
Medical Science and Discovery
Open Access Scientific Journal
August 2015, Vol.2, No.4

www.medscidiscovery.com

Medical Science and Discovery (<http://www.medscidiscovery.com>) is an international open access, peer-reviewed scientific research journal that provides rapid publication of articles in all disciplines of human health, clinical and basic medical science such as Biophysics, Biochemistry, Histology, Physiology, Genetics, Pathology, Toxicology, Anatomical Sciences, Pharmacology, Embryology, Internal and Surgical Medicine.

The policy of top priority of MSD is to put forward and highlight medical innovations and inspiring patents.

MSD offers an exceptionally fast publication schedule including prompt peer-review by the experts in the field and immediate publication upon acceptance. The editorial board aims at reviewing the submitted articles as fast as possible and promptly including them in the forthcoming issues.

This journal is published under ethical publishing policy of international scientific Bioethics and publication rules.

MSD supports the Open Access Initiative. Abstracts and full texts (HTML and PDF format) of all articles published by MSD are freely accessible to everyone immediately upon publication.

Medical Science and Discovery is affiliated with [Celal Bayar University Faculty of Medicine](#)

Founder: **Independent**

Publisher: **Lulu Press, USA**

Country of Publication: **Turkey**

Sponsor: **TUTKU SAĞLIK GEREÇLERİ TİCARET A.Ş** <http://www.tutkusaglik.com/>

Editor in Chief and Chairman

Zafer AKAN (Asist. Prof. Dr.) CBU, Faculty of Medicine Dept. of Biophysics, Manisa, TURKEY

Deputy Editor

Mehmet Bilgehan YUKSEL (Asist. Prof. Dr.) CBU, Faculty of Medicine Dept. of Urology, Manisa, TURKEY

Honorary Editors

Prof. Dr. Metin TULGAR, YYU Faculty of Medicine, Dept. of Biophysics, Van, TURKEY

Prof. Dr. Giancarlo BAROLAT, Barolat Neuroscience Institute, Denver, Colorado, USA

Prof. Dr. Joyce REARDON, UNC School of Med. Dept. Of Biochemistry-Biophysics North Carolina, USA

Associate Editors

Prof. Dr. Arash KHAKI, Tabriz University, Faculty of Medicine, Dept. of Pathology, Tabriz, IRAN

Prof. Dr. Nobuo Inotsume, Hokkaido Pharmaceutical University School of Pharmacy, Division of Clinical Pharmacology, Otaru, Japan

Asist. Prof. Dr. Secil ILHAN YILMAZ, Erciyes University, Genom and Stem Cell Research Center

Asist. Prof. Dr. Younès Elbouzekri EL IDRISSE, Università degli Studi di Genova, ITALY

Asist. Prof. Dr. Yusuf Kemal DEMİR, Australian Government End. Research Fellow. Faculty of Pharmacy, AUSTRALIA

Statistical Editor

Asc. Prof. Dr. Siddik Keskin YYU Faculty of Medicine Dept. of Biostatistics, Van, TURKEY

Language Editor

Asist. Prof. Dr. Hakan Ergin Istanbul University Dept. of Foreign Languages, Fatih, Istanbul, TURKEY

All the financial and ethical rights of the journal are reserved for the private ownership of MSD

Adress: Celal Bayar University, Faculty of Medicine Dept. of Biophysics, Uncubozkoy 45080 Manisa-Turkey

Tel: +90-236-2011000/213

Fax: +90-236-2372442

E-mail: editor@medscidiscovery.com

Editorial Board

Internal Medicine

| | | |
|------------------|----------------------|--|
| Asist. Prof. Dr. | Adem ŞENGÜL | Izmir Yesilyurt State Hospital Dept. of Radiation Oncology |
| Asist. Prof. Dr. | Ahmet ÇİNKAYA | CBU, Faculty of Medicine, Dept. of Radiation Oncology |
| Asist. Prof. Dr. | Ahmet YILMAZ | Dicle University, Faculty of Medicine, Dept. of Family Medicine |
| Asc. Prof. Dr. | Alparslan ŞAHİN | Dicle University, Faculty of Medicine, Dept. of Eye |
| Asist. Prof. Dr. | Gökmen BILGILI | CBU, Faculty of Medicine, Dept. of Neonatology |
| Prof. Dr. | Hasan YUKSEL | CBU, Faculty of Medicine, Dept. of Pediatric Allergy, Resp. dis. |
| Prof. Dr. | Hikmet YILMAZ | CBU, Faculty of Medicine, Dept. of Neurology |
| Asist. Prof. Dr. | M. Ziya KIR | CBU, Faculty of Medicine, Dept. of Forensic Medicine |
| Asist. Prof. Dr. | Murat ÖZSARAÇ | CBU, Faculty of Medicine, Dept. of Emergency Medicine |
| Prof. Dr. | Muzaffer POLAT | CBU, Faculty of Medicine, Dept. of Pediatric Neurology |
| Asc. Prof. Dr. | Ömür Karakoyun ÇELİK | CBU, Faculty of Medicine, Dept. of Radiation Oncology |
| Prof. Dr. | Sırrı ÇAM | CBU, Faculty of Medicine, Dept. of Genetic |
| Asist. Prof. Dr. | Tarık ULUCAY | CBU, Faculty of Medicine, Dept. of Forensic Medicine |
| Asist. Prof. Dr. | Yalçın GÖLCÜK | CBU, Faculty of Medicine, Dept. of Emergency Medicine |

Basic Sciences

| | | |
|------------------|----------------------|--|
| Prof. Dr. | Ahmet VAR | CBU, Faculty of Medicine, Dept. of Biochemistry |
| Dr. | Alper Tunga ÖZDEMİR | Manisa ME State Hospital Dept. of Medical Biochemistry |
| Asc. Prof. Dr. | Ayşe Inhan GARİP | Marmara University, Faculty of Medicine, Dept. of Biophysics |
| Asist. Prof. Dr. | Bahriye SİRAN | Gazi University, Faculty of Medicine, Dept. of Biophysics |
| Prof. Dr. | Beki KAN | Acıbadem University, Faculty of Medicine, Dept. of Biophysics |
| Prof. Dr. | Cevval ULMAN | CBU, Faculty of Medicine, Dept. of Biochemistry |
| Asc. Prof. Dr. | Gultekin YEĞİN | CBU, Faculty of Art and Science, Dept. of Physics |
| Prof. Dr. | Halit DEMİR | YYU Faculty of Science, Dept. of Biochemistry |
| Research Ast. | Hasan DEMİROĞLU | CBU, Faculty of Art and Science, Dept. of Chemistry |
| Research Ast. | Muhammet Burak BATIR | CBU, Faculty of Medicine, Dept. of Genetic |
| Prof. Dr. | Mustafa ÖZBEK | CBU, Faculty of Medicine, Dept. of Physiology |
| Prof. Dr. | Necip KUTLU | CBU, Faculty of Medicine, Dept. of Physiology |
| Dr. | Ömer KAÇAR | TUBİTAK MAM Dept. of Molecular Biology |
| Dr. | Özdemirhan Serçin | Interdisciplinary Research Institute, Université Libre de Bruxelles, Belgium |
| Prof. Dr. | Seda VATANSEVER | CBU, Faculty of Medicine, Dept. of Histology and Embryology |
| Prof. Dr. | Selim UZUNOĞLU | CBU, Faculty of Medicine, Dept. of Medical Biology |
| Prof. Dr. | Sevinç İNAN | CBU, Faculty of Medicine, Dept. of Histology and Embryology |
| Asist. Prof. Dr. | Sule ONCUL | Istanbul Medeniyet University, Faculty of Medicine, Dept. of Biophysics |
| Asist. Prof. Dr. | Tahir Cakir | YYU Faculty of Medicine, Dept. of Biophysics, Van |
| Asc. Prof. Dr. | Tamer ZEREN | CBU, Faculty of Medicine, Dept. of Biophysics |
| Asc. Prof. Dr. | Uğur AVCIBAŞI | CBU, Faculty of Art and Science, Dept. of Chemistry |

Surgical Medicine

| | | |
|------------------|---------------------|---|
| Dr. | Christopher Schmitt | University of California, San Francisco Cardiovascular Res. Inst. |
| Prof. Dr. | Cüneyt TEMİZ | CBU, Faculty of Medicine, Dept. of Neuro Surgery |
| Prof. Dr. | Çetin DİNÇEL | Hacettepe University, Faculty of Medicine, Dept. of Urology |
| Prof. Dr. | Gönül Tezcan KELEŞ | CBU, Faculty of Medicine, Dept. of Anesthesiology and Rean. |
| Asc. Prof. Dr. | İlhan GEÇİT | YYU Faculty of Medicine, Dept. of Urology |
| Prof. Dr. | M. Derya BALBAY | Memorial Hospital, Dept. of Urooncology |
| Asist. Prof. Dr. | Murat YILDIR | BAU Faculty of Medicine, Dept. of General Surgery |
| Prof. Dr. | Nasuhi Engin AYDIN | Katip Çelebi University, Faculty of Medicine, Dept. of Pathology |
| Asc. Prof. Dr. | Necip PİRİNÇÇİ | YYU Faculty of Medicine, Dept. of Urology |
| Prof. Dr. | Taçkın ÖZALP | CBU, Faculty of Medicine, Dept. of Orthopedic Surgery |

Statistical Editor

| | | |
|-----------|---------------|--|
| Prof. Dr. | Sıddık KESKİN | YYU Faculty of Medicine, Dept. of Medical Statistics |
|-----------|---------------|--|

Language Editor

| | | |
|------------------|-------------|---|
| Asist. Prof. Dr. | Hakan ERGİN | Istanbul University, Dept. of Foreign Languages |
|------------------|-------------|---|

Editorial Office

| | | |
|-------------|------------|--------------------------|
| Asist. Res. | Taner Özel | CBU, Faculty of Medicine |
|-------------|------------|--------------------------|

Instruction for Authors

- MSD Publications uses CrossCheck's iThenticate software to detect instances of similarity in submitted manuscripts. In publishing only original research, MSD is committed to deterring plagiarism, including self-plagiarism. Your manuscript may be screened for similarity to published material.
- **Manuscript Preparation :**
- Manuscripts should be prepared in accordance with the "Uniform Requirements for Manuscripts Submission to Biomedical Journals" proclaimed by the International Committee of Medical Journal Editors (www.icmje.org).
- **1. Cover letter**
- **a-** A statement that the manuscript has been read and approved by all the authors.
- **b-** That the requirements for authorship have been met for all the authors, based on the criteria stated by *ICMJE*.
- **c-** Approval of all the authors regarding the order in which their names have appeared.
- **d-** That each author confirms the manuscript represents honest work.
- **e-** The name, address, and telephone number of the corresponding author who is responsible for communicating with other authors about revisions and final approval.
- **f-** The letter should give any additional information that may be helpful to the editor, such as the type or format of the article. If the manuscript has been submitted previously to another journal or in another language, it is helpful to include the previous editor's and reviewers' comments with the submitted manuscript, along with the authors' responses to those comments. Submitting previous evaluatory review of another journal accelerates the review process.
- **g-** For accepted manuscripts, the authors are requested to fill and sign the journal's cover letter to express their consent for its publication.
- **h-** To reproduce published material, to use illustrations or tables or report information about identifiable people, the author should submit a copy of the permission with the manuscript to the journal.
- **2. Top Ethic Committee Approval**
Inclusion of the approval letter from the relevant Ethics Committee or Institution's Review Board regarding the research protocol and the rights of the subjects (if applicable to the study)
- **3. Top Consent Form**
Attach a copy of the consent form to the letter, if applicable. Consent forms would be evaluated by the Ethics Committee and then signed by the participant.
- **4. Top RCT or NCT Registration**
Emailing the letter denoting registration of RCTs or NCTs in domestic or international databases (The trial's registration number needs to be mentioned, too).
- 5. Manuscripts submitted in English, must be type written, double-spaced, on good quality A4 paper, or paper of similar format. Authors are requested to reserve margins of at least 2.5cm all around the paper. Original drawings of photos, tables and figures should be furnished together with the manuscripts.
- 6. Manuscripts should be kept to a minimum length and should be subdivided into labeled sections (Title page, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement, and References).
- 7. A title page is to be provided and should include the title of the article, authors' names with full first name (with degrees), authors' affiliation, suggested running title and corresponding author. The affiliation should comprise the department, institution (usually university or company), city and state (or nation). The suggested running title should be less than 50 characters (including spaces) and should comprise the article title or an abbreviated version thereof. For office purposes, the title page should include the name and complete mailing address, telephone and fax number, and email of the one author designated to review proofs.
- 8. An abstract no longer than 250 words for reviews and research articles is to be provided as the second page. Abstract should be structured as objective(s) (including purpose setting), materials and methods, results, and conclusion.
- 9. A list of 3-8 keywords, chosen from the Medical Subject Headings (MeSH) list <http://www.nlm.nih.gov/mesh/MBrowser.html>, is to be provided directly below the abstract. Keywords should express the precise content of the manuscript, as they are used for indexing purposes. Provide abbreviations and nomenclature list in an alphabetical order and non-standard abbreviations contained in the manuscript (excluding references) with definitions after the keywords. Use abbreviations sparingly and only when necessary to save space, and to avoid repeating long chemical names or therapeutic regimes. In a figure or table, define the abbreviations used in a footnote.
- 10. Tables in limited numbers should be self-explanatory, clearly arranged, and supplemental to the text. The captions should be placed above.
- 11. Figures should be utilized only if they augment understandability of the text. The captions should be placed below. Drawings and graphs should be professionally prepared in deep black and submitted as glossy, black and white clean Photostats. Professionally designed computer generated graphs with a minimum of 300 DPI laser printer output is preferable. Color photographs are welcomed.
- 12. The same data should not be presented in tables, figures and text, simultaneously.

Instruction for Authors

- 13. MSD uses **Vancouver** referencing Style. References in limited numbers and up-to-dated must be numbered consecutively in order of citation in the text (number in parentheses). Periodical titles should be abbreviated according to the PubMed Journals Database (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=journals>). Print surnames and initials of all authors when there are six or less. In the case of seven or more authors, the names of the first six authors followed by et al. should be listed.
- Please check all references with EndNote referencing System. Please check out and [Download Vancouver Endnote Style](#)
- **TYPE OF ARTICLES:**
- Type of articles are based on PubMed definitions. For more info please refer to: <http://dtd.nlm.nih.gov/publishing/tag-library/3.0/n-w2d0.html>
- **Editorial :**
- Editorial is Opinion piece, policy statement, or general commentary, typically written by staff of the publication (The similar value "article-commentary" is reserved for a commentary on a specific article or articles, which is written by an author with a contrasting position, not an editor or other publication staff.)
- **Letters to the Editor about a recent journal article :**
- Letters referring to a recent article in this journal must be received within three months of its publication. For example, a letter referring to an article published in the January issue must be submitted online no later than March 31st. Letters submitted after the allowed time will not be considered.
- The text, not including references, must not exceed 700 words. A maximum of three authors and 10 references are allowed. Neither tables nor figures are allowed.
- **Letters to the Editor NOT referring to a recent journal article :**
- Original research that is of interest but does not fulfill all the requirements needed for publication as a full-length manuscript can be submitted as a letter to the editor. The letter must have a title and a maximum of three authors.
- The text, not including references, tables, figures or legends must not exceed 700 words. No more than 10 references and either one table or one figure are allowed.
- Word Count Limit: Letters should contain 500 - 700 words, maximum number of references is 10, maximum Number of illustrations/Tables is 1.
- **Original :**
- The content of the paper must justify its length. For reports of original investigative work, traditional division into sections is required: Title, Keywords, Addresses and which author address for correspondence, Structured abstract, Background, Objectives, Materials/Patients and Methods, Results, Discussion, References and Acknowledgements, Legends for display items (Figures and Tables).
- Research articles should contain 2500 - 3500 words, maximum number of references is 35, maximum Number of illustrations/Tables is 5.
- **Review Article :** Review Articles should contain 3500 - 4000 words, maximum number of references is 50, maximum number of illustrations/Tables is 5. In a review article both abstract and text of the manuscript, include following items:
- 1) Context: Include 1 or 2 sentences describing the clinical question or issue and its importance in clinical practice or public health.
- 2) Evidence Acquisition: Describe the data sources used, including the search strategies, years searched, and other sources of material, such as subsequent reference searches of retrieved articles. Explain the methods used for quality assessment and the inclusion of identified articles.
- 3) Results: Address the major findings of the review of the clinical issue or topic in an evidence-based, objective, and balanced fashion, emphasizing the highest-quality evidence available.
- 4) Conclusions: Clearly state the conclusions to answer the questions posed if applicable, basing the conclusions on available evidence, and emphasize how clinicians should apply current knowledge.
- **CASE REPORT :**
- A case report is a case study, case report, or other description of a case that should contain 1500 - 2000 words with a structured abstract of 200 words maximum. Case reports should comprise sections of Introduction, Case Presentation, and Conclusions in Abstract and Introduction, Case Presentation, and Discussion in full text with not more than 2 tables or figures and up to 20 references.
- **Brief Report :**
- Brief Reports should contain 1000 - 2000 words with a structured abstract of 200 words maximum. Short reports should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.

Instruction for Authors

- **Short Communication :**
- Short Communication, follow the instructions for original articles, except that the total word number of the main text (excluding references, tables and figure legends) is limited to 2000 with no more than 2 figures and/or tables and no more than 15 references. An abstract, not exceeding 150 words, should be presented at the beginning of the article.
- **News :**
- News should contain 1000 - 2000 words with a structured abstract of 200 words maximum. News should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.
- **Submission and Review Process :**
- Manuscripts must be written in English (use consistently either British or American spelling) and must be submitted online. To submit, go to <http://medscidiscovery.com/journal/index.php/medsci/user/register>. Full instructions for submission are detailed on submission system.
- **C. General Consideration:**
- **1. Peer review process:** All submissions will be reviewed anonymously by at least two independent referees. All manuscripts will be acknowledged upon presenting to the Journal office, provided that all stated requirements are met. Authors are encouraged to suggest names of three expert reviewers, but selection remains a prerogative of the Editor. The whole review process depends on receiving referees comments and revising the manuscripts based on these comments to the author. On receipt of the revised article from the author, and after final approving by referees, the letter of acceptance is issued to the author. Authors have the right to communicate to the editor if they do not wish their manuscript to be reviewed by a particular reviewer because of potential conflicts of interest. No article is rejected unless negative comments are received from at least two reviewers.
- **2. Conflicts of interest:** Authors should disclose, at the time of submission, information on financial conflicts of interest or other interests that may influence the manuscript. Authors should declare sources of funding for the work undertaken.
- **3. The Journal's Policy on Plagiarism:** Any practice of plagiarism will not be tolerated by the journal regarding submitted manuscripts. Non-identifiable quoted segments of articles or close paraphrases from other author/s or even submitting the author's previously published work are known as the act of plagiarism by this journal unless proper use of quotations or paraphrasing with decent citation or referencing are in place. Heavy use of one or a couple of articles is discouraged, even if paraphrased fully. Advertent practice of plagiarism will abort reviewing process or later submission to this journal. All submitted articles will evaluate by *iThenticate* software belonged to cross check for stop any plagiarism and improve publication quality.
- **4. Ethical consent:** All submitted articles involving human experiments should be performed only in accordance with the ethical standards provided by the responsible committee of the institution and in accordance with the Declaration of Helsinki (as revised in Edinburgh 2000), available at <http://www.wma.net/en/30publications/10policies/b3/index.html>. Papers describing animal experiments can be accepted for publication only if the experiment conforms the National Institute of Health Guide (National Institute of Health Publications No. 80-23, Revised 1978) for the care and use of Laboratory Animals for experimental procedure. Authors must provide a full description of their anesthetics and surgical procedures. All manuscripts reporting the results of experimental investigations involving human subjects should include a statement confirming the informed consent was obtained from each subject or subject's guardian. All animal or human studies should be used after approval of the experimental protocol by a local ethics committee
- **5. Acknowledgements:** Contributors: In acknowledgement section, name people for their contributions or their permission to reproduce their published material, to use their illustrations or provide information about them- try to fully name people who have helped from the conception of the idea to adoption of the hypothesis, to finalization of the study, etc., earnestly. Statement of financial support: Aside from the title page, state any financial or other relationships that might lead to a conflict of interest.
- **6. Copyright: Please complete copyright form and send via email to editor.** [Download MSD Copyright Form](#)
- **7. Disposal of material:** Once published, all copies of the manuscript, correspondence and artwork will be held for 6 months before disposal.
- 8. This journal is licensed under a [Creative Commons Attribution License](#).
- 9. Once a manuscript is accepted for publication it will be provided with a registered DOI number following the acceptance decision. Manuscripts accepted for publication by the **MSD** will be published as ahead of print articles prior to the printing date of their scheduled issue. Corresponding author will be provided with a PDF Proof by the publisher once the production process of an accepted manuscript is over.

Instruction for Authors

- **10. Briefly Sections of MSD article:**
- Sections of article should insert into just one word document and uploaded to MSD submission system as manuscript document. Title page will detach from manuscript by MSD editors and manuscript will forward to referees without title page due to double blinded review rules.
- **1-Title Page Section**
- Article Type:
- Title of Article:
- Name Surname of Author¹, Name Surname of Author², ...
- ¹Author Name Surname, Affiliation, e-mail address
- ²Author Name Surname, Affiliation, e-mail address
- *Corresponding Author :
- Author Name Surname, Affiliation, Address, Phone, Fax, E-mail address,
- Corresponding Author should upload all file
- **2-Manuscript Section**
- Abstract (Objective: Methods: Results: Conclusion: "200 words and Key words)
- Introduction, Material and Methods, Statistic, Results, Discussion, Acknowledgement, References
- **3-Table and Figures Section**
- Tables and Legends, Figures and Legends
- **11. Article Processing Charge**
- MSD is a non-profit Scientific Journal Platform; however, it uses professional services such as Language Editing, DOI, domain and hosting Services, iThenticate Plagiarism or similarity detection Software. All of these professional services are used for all the article processes and an inevitable cost arises with this.
- Unfortunately, like most open journals, fees of the publication with MSD are charged to Authors. Payment is under the responsibilities of corresponding Author(s). MSD does not charge any fee during the submission period. However, after the peer-review process, a non-refundable charge (100 USD) for each accepted manuscript must be paid by the author(s) via MSD's official PayPal account. An invoice will be sent for each accepted manuscript to corresponding author(s).

Contents

Hypothesis

- 1 Believing (faith or hypnosis) that impacts on the healing of warts performed by neurophysiological mediators
Huseyin Guducuoglu, Serap Gunes Bilgili, Mehmet Arslan
Medical Science and Discovery, August 2015; 2(4): 236-38

Review Article

- 2 Anesthesia Management of Patients with Mental Retardation
Nureddin Yuzkat, Muhammed Bilal Cegin
Medical Science and Discovery, August 2015; 2(4): 239-43

Original Articles

- 3 Effect of Acetaminofen Versus Lornoxicam Administration on Oxidative Stress in Rat Hepatic and Renal Tissues
Mustafa Sancar Atac, Saban Cem Sezen, Mustafa Bilge, Berrin Isik, Mustafa Arslan, Faruk Metin Comu, Mustafa Kavutcu, Dervis Yilmaz
Medical Science and Discovery, August 2015; 2(4): 244-53
- 4 Coronary artery bypass surgery and sexual function
Mehmet Bilgehan Yuksel, Ilhan Gecit, Ayhan Karakose, Necip Pirincci, Mustafa Gunes, Cemalettin Aydin, Mehmet Kaba
Medical Science and Discovery, August 2015; 2(4): 254-59
- 5 Retrospective analysis of deep sedation in pediatric population for endoscopic procedures: adverse events and outcomes
Berrin Isik, Volkan Sivgin, Mustafa Arslan, Seyfi Kartal, Yusuf Unal, Mehmet Akcabay
Medical Science and Discovery, August 2015; 2(4): 260-66
- 6 Relationship Between Premature ventricular complexes and Neutrophil Lymphocyte Ratio in asymptomatic healthy young men
Erkan Kibrisli, Ahmet Yilmaz, Sinan Iscen, Salim Ozenc, Duran Tok, Adem Parlak
Medical Science and Discovery, August 2015; 2(4): 267-70

Case Reports

- 7 Delayed organophosphate - induced polyneuropathy
Abuzer Coskun, Afsin Emre Kayipmaz, Sedat Ozbay, Osman Mahir Okur, Ilham Ozkan, Sevki Hakan Eren
Medical Science and Discovery, August 2015; 2(4): 271-74
- 8 Treatment Of Postoperative Atelectasis With Dornase Alpha (Pulmozyme) After Congenital Heart Surgery
Mustafa Hakan Zor, Abdullah Ozer, Huseyin Demirtas, Yigit Kilic, Baris Mardin
Medical Science and Discovery, August 2015; 2(4): 275-77
- 9 Cyst Hydatid Case Ruptured After Awake Intubation Causing Difficult Airway
Nureddin Yuzkat, Muhammed Bilal Cegin
Medical Science and Discovery, August 2015; 2(4): 278-80

Believing (faith or hypnosis) impacts on the healing of warts performed by neurophysiological mediators

Huseyin Guducuoglu¹, Serap Gunes Bilgili², Mehmet Arslan³

Abstract

Background: Faith and hypnosis methods are applied in many experimental cancer treatments. Practices of religious and psychological healing have a major role in the recovery of tumors. Healing warts by prayer has been used for years, particularly in the Turkish society.

The Hypothesis: This hypothesis maintains that believing is one of the key concepts in the recovery of tumors and also focuses on the effect of believing on the recovery of warts

Evaluation Hypothesis: In people who believe, nerve, endocrine and immune system is activated. NK and T cells in the periphery cause destruction in the wart tissue and also lead to healing in all tissues. According to our hypothesis, believing is the actual trigger for the healing of warts. Both the prayer and the hypnosis methods, in terms of cancer improvement, have been shown in many publications in the literature and have brought a new dimension to cancer recovery.

Conclusion: We hypothesize that believing (prayer or hypnosis) can be effective on the healing of warts through the stimulation of the immune system.

Key words: Warts healing, Believing, Hypnosis

Introduction

The National Center for Complementary and Alternative Medicine (NCCAM) defines complementary and alternative medicine (CAM) as “a group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine” (1). Over the last years, the use of CAM for dermatological diseases has remarkably increased (2). Moreover, a significant relationship has been found between some forms of unconventional therapy and some skin disorders, including generalized pruritus and application of cologne, warts and spiritual healing; fungal infections and application of henna, psoriasis and herbal therapy, or spiritual healing; alopecia areata and application of garlic, acne and application of lemon juice, clay, or cosmetics (3).

In the treatment of warts, prayer is a method of unconventional therapy and is frequently used by many people. There is also another concept named “intercessory prayer”, which means that a person performs prayer for the benefit of another person. Many people believe that intercessory prayer is very effective in recovering from illnesses (4,5), particularly in the Turkish society (6). In a study on the use of hypnoanalysis, 33 of 41 (80%) consecutive

patients were cured, two were lost to follow-up, and six did not respond to treatment (7). Another study investigated the effect of hypnosis on immunity in order to find out whether this effect is the key mechanism in the hypnotic treatment of the genital infection caused by human papillomavirus (HPV). The study reported that hypnosis and medical therapy resulted in a statistically significant reduction both in the surface areas and the numbers of lesions (8).

The hypothesis

Believing is a crucial part of prayer and hypnosis. When the person truly believes in prayer, some molecules trigger immune responses in the brain and consequently some molecules are synthesized in the brain and induce a variety of immune system cells in the body. As a result, the disappearance of warts becomes obvious. Moreover, when the person focuses on believing while performing prayers or hypnosis, a number of mediators are secreted from the brain (immunoregulatory neuropeptides) and these mediators facilitate the healing of cancer cells by activating several immune system cells such as NK and T cells.

Received: 01-04-2015, Accepted 12-05-2015, Available Online 01-06-2015

¹Yüzüncü Yıl University, School of Medicine Basic Microbiology Dep., Van.

²Yüzüncü Yıl University, School of Medicine Dermatology Dep., Van.

³Yüzüncü Yıl University, School of Medicine Neurosurgery Dep., Van.

*Corresponding Author: Huseyin Guducuoglu E-mail: hguducu@hotmail.com

Evaluation of the hypothesis

Most people discuss the effectivity of the procedures used in cancer treatment, but they still ignore the real power of immunity. In some societies, people employ religious methods to eradicate tumors, particularly warts. Nevertheless, to date, no correlation, such as a relationship between the immune response and the eradication of warts, has been clearly explained in any study. However, since medical treatment is the primary method of choice in tumor therapy, believing (prayer or hypnosis) can be used a supportive therapy for enhancing the immunological effects during the healing process.

Traditional methods are commonly used for the eradication of lesions like warts. It is claimed that believing in the prayer method is the key to success in the recovery of warts. Both the prayer and the hypnosis method, in terms of cancer improvement, have been shown in many publications in the literature and have brought a new dimension to cancer recovery. This dimension will open new doors for the intensive studies to be undertaken on the effectivity of believing on the neurophysiological mediators and cancer recovery.

Discussion

Hypnosis and prayer employ the same path for providing effects on the recovery of illnesses. Barabasz et al. suggest the following hypnotic method for both groups; “Your body has the capacity to overcome the wart virus and to heal the infection. Focus your attention and concentrate on the involved area [pause]. Soon, you may notice a sensation of warmth in the surrounding skin [pause]. Your blood vessels dilate to bring in more and more antibodies and white blood cells; more lymphocytes and natural killer cells [pause]. The virus will be destroyed and carried away [pause]. Protein and oxygen will increase to help build the new, normal, healing tissue as the warts disappear. When you feel the increased warmth, a finger will rise [after observation of finger raise] good. Now your inner mind will lock in on this and maintain this special warmth until the warts are all healed and your skin becomes normal in every way” (8).

In the prayer method, believing in God and the prayers is the key to the healing of warts. A similar study reported that the participants prayed to God via an intercessor (an imam) and their warts were thus recovered. The study also reported that no effects were seen in the participants who did not trust the intercessor’s prayers (5). Therefore, believing is a key issue both for prayer and hypnosis.

When the person truly believes in prayer, the nervous, endocrine, and immune systems interact to adapt to infection, inflammation, and tissue injury. Neural control is mediated in several ways: through

the neuroendocrine regulation of the secretion of hypothalamic and pituitary hormones, autonomic nervous system-induced activation of epinephrine secretion and of peripheral sympathetic fibers that innervate lymphoid tissue, and sensory neurons that secrete immunoregulatory neuropeptides such as substance P and somatostatin. These regulatory interactions influence the manifestations and course of disease (9). Substance P and other neuropeptides activate neurokinin-1 receptors, leading to plasma protein extravasation from post-capillary venules. Substance P is a neuropeptide that is released from nerve endings in many tissues and plays an important role in immunological and inflammatory states, and it is also a mediator of tissue injury, asthma, arthritis, allergy and autoimmune diseases (10).

In a similar way, products of hypothalamic-pituitary-adrenal activation may be important factors contributing to the resistance of the negative feedback of cortisol on CRH and ACTH secretion associated with depression, and these products may be involved in psychological distress through their effects on serotonin (11). Serotonin, as a neurotransmitter, is thought to cause depression and serotonin reuptake inhibitors, which increase the availability of this transmitter in the synaptic cleft and alleviate the symptoms. Melatonin, which is a hormone secreted by the pineal gland, is best known for its functions in synchronizing the circadian clock and has been implicated in the pathogenesis of cancer. Melatonin is a product of serotonin metabolism. In the biosynthesis of melatonin, the rate-limiting step is the conversion of serotonin to N-acetylserotonin, catalyzed by N-acetyltransferase (12).

HPV-associated malignancies and breast cancers may be more susceptible to immune effects and to the modulation caused by stress and psychological factors. Developments in cancer immunology call attention to other scenarios as well. Accordingly, although a competent immune response may favor eradication of malignant foci, the increased selection pressure may also yield more aggressive and resistant tumor cells. Animal models of cancer progression are instrumental in suggesting neuroendocrine and immunological mediators of stress effects on specific aspects of cancer progression, especially with respect to the role of Natural Killer (NK) cell activity (13).

Very preliminary data seem to show that lymphocyte proliferation and activation may be influenced by the psychological status of the patients. Some cancers like lung cancer may depend not only on tumor characteristics, but also on the psychospiritual status of the individual patient by influencing the immune and neuroendocrine functions, which plays a fundamental role in the control of neoplastic growth (14). Psychoneuroimmunology is the study of interaction between psychological processes and the nervous and immune systems of the

human body. Communication between the mind and the skin involves the psycho-immuno-endocrine-cutaneous system, encompassing the activities of the brain, the immune system and the skin, with participation of different neuropeptides, interleukins, and immune system messengers (15).

Immunity leading to wart regression is essentially universal but poorly understood. Cellular and cytotoxic immunity provided by T cells and NK cells are necessary for the control of HPV infections, but the exact mechanisms are unknown (16). For the past few decades, scientific investigations on CAM have remarkably advanced and partly supported their medical efficacy through preclinical and clinical experiments. In particular, many investigators have suggested that NK cell activation is one of the critical mechanisms for the biological effects induced by various CAM agents (17). Therefore, NK and T cells are likely to have a major role in the destruction of warts and thus further studies on wart healing are warranted to focus on these cells.

This hypothesis takes its virtue from the common believing among Turkish people that warts heal via prayers without using any medical treatment. This hypothesis is unique because it will provide important suggestions for future studies.

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. National Center For Complementary and alternative medicine. What is complementary and alternative medicine (CAM)? Publication No. D156. 2002, URL: <http://nccam.nih.gov/health/whatiscam/> (accessed 30 January 2008).
2. Magin PJ, Adams J, Heading GS, Pond DC, Smith W. Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients' experiences and perceptions. *J Altern Complement Med*, 2006, 12: 451–457.
3. Gönül M, Gül U, Cakmak SK, Kiliç S. Unconventional medicine in dermatology outpatients in Turkey. *Int J Dermatol*, 2009, 48(6):639–44.
4. Benson H., Dusek J. A., Sherwood J. B., et al. Study of the therapeutic effects of intercessory prayer (STEP) in cardiac bypass patients: A multicenter randomized trial of uncertainty and certainty of receiving intercessory prayer. *American Heart Journal*, 2006, 151(4): 934–942.
5. Hoşrik EM, Cüceloğlu AE, Erpolat S. Therapeutic Effects of Islamic Intercessory Prayer on Warts. *J Relig Health*, 2014, Feb 18. [Epub ahead of print]
6. Bilgili SG, Ozkol HU, Karadag AS, Calka O. The use of complementary and alternative medicine among dermatology outpatients in Eastern Turkey. *Hum Exp Toxicol*, 2014, 33(2):214–21.
7. Ewin DM. Hypnotherapy for warts (*verruca vulgaris*): 41 consecutive cases with 33 cures. *Am J Clin Hypn*, 1992, 35(1):1–10.
8. Barabasz A, Higley L, Christensen C, Barabasz M. Efficacy of hypnosis in the treatment of human papillomavirus (HPV) in women: rural and urban samples. *Int J Clin Exp Hypn* 2010, 58(1):102–21.
9. Levin J. How faith heals: a theoretical model. *Explore (NY)*. 2009, 5(2):77–96.
10. Castellani ML, Galzio RJ, Felaco P, Tripodi D, Toniato E, De Luttis MA, Conti F, Fulcheri M, Conti C, Theoharides TC, Caraffa A, Antinolfi P, Felaco M, Tete S, Pandolfi F, Shaik-Dasthagirisahab YB. VEGF, substance P and stress, new aspects: a revisited study. *J Biol Regul Homeost Agents*, 2010, 24(3):229–37.
11. Hurwitz EL, Morgenstern H. Immediate and longterm effects of immune stimulation: hypothesis linking the immune response to subsequent physical and psychological wellbeing. *Med Hypotheses*, 2001, 56(6):620–4.
12. Panzer A. Depression or cancer: the choice between serotonin or melatonin? *Med Hypotheses*, 1998, 50(5):385–7.
13. Ben-Eliyahu S, Page GG, Schleifer SJ. Stress, NK cells, and cancer: Still a promissory note. *Brain Behav Immun*, 2007, 21(7):881–7.
14. Lissoni P, Messina G, Balestra A, Colciago M, Brivio F, Fumagalli L, Fumagalli G, Parolini D. Efficacy of cancer chemotherapy in relation to synchronization of cortisol rhythm, immune status and psychospiritual profile in metastatic non-small cell lung cancer. *In Vivo*, 2008, 22(2):257–62.
15. Lugović-Mihić L, Ljubesić L, Mihić J, Vuković-Cvetković V, Troškot N, Situm M. Psychoneuroimmunologic aspects of skin diseases. *Acta Clin Croat*, 2013, 52(3):337–45.
16. Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. *J Allergy Clin Immunol*, 2012, 130(5):1030–48.
17. Cooper EL. The immune system and complementary and alternative medicine. *Evid Based Complement Alternat Med*, 2007, 4(Suppl 1):5–8.

Anesthesia Management of Patients with Mental Retardation

Muhammed Bilal Cegin¹, Nureddin Yuzkat^{1*}

Abstract

Mental retardation is a condition likely to develop secondarily to several genetic diseases or to some negative conditions and diseases that occur before, during or after birth. Anaesthetic practices start with the preoperative visit of a patient and are then followed by premedication, preoperative preparation, intraoperative procedures and postoperative periods. All these steps with mentally retarded patients involve separate characteristics. The MR patients must be kept under observation in the recovery rooms for longer periods of time and must also be definitely re-evaluated by an experienced anaesthetist before being transferred to the service department. Since there may be several challenges/difficulties likely to be experienced at each stage of the mentally retarded patients' anaesthesia, far more care and patience is required. A pre-anaesthetic evaluation involving a physical examination in depth and a detailed questioning should be performed. During the pre-medication period, a little amount of midazolam mixed with a proper drink can be used. Prior to applying the neuromuscle blocking agents, the airway opening must be maintained. In the presence of muscular dystrophies, the doses of neuromuscular blocking agents must be equalized. The MR patients must be kept under observation in the recovery rooms for longer periods of time and must also be definitely re-evaluated by an experienced anaesthetist before being transferred to the service department.

Key words: Anesthesia management, Mental retardation, Intelligence quotient

Introduction

The patients with mental retardation have a special place in anesthetic management. Mentally retarded patients might be seen at both operation rooms and outpatient anesthesia managements. There are a limited number of data in the literature about the anesthetic management of mentally retarded patients. We think this article would be helpful for recognition of mental retardation.

Definition and Classification: Mental retardation (MR) is a condition likely to develop secondarily to several genetic diseases or to some negative conditions and diseases that occur before, during or after birth. According to the data of The World Health Organization (WHO), 3% of the world's population consists of mentally retarded people at various levels. Patients usually show themselves with intellectual deficiencies (ID), retardation in mentality and social inadaptability. Such disorders may develop in association with the exposure of the intrauterine to toxic substances, infections experienced during the gestational period, problems faced at the time of birth, or a trauma, infection or other diseases experienced in any period after birth/delivery (1).

Mental retardation is defined according to the Intelligence Quotient (IQ) scores, or by being categorized with the terms like trainable, educable and totally in need of care (Table 1). Despite this, dealing with each individual and caring for them with the help of an independent evaluation in the classification process would be a better and more accurate approach (2)

Anaesthesia: Anaesthetic practices start with the preoperative visit of a patient and are then followed by premedication, preoperative preparation, intraoperative procedures and postoperative periods. At each step of these procedures, the patient and patient relatives must be informed about the processes to take place and the complications that may occur (3). All these steps with mentally retarded patients involve separate characteristics.

Preoperative visit comprises the steps, such as the specification of the drugs used by the patient, previously-undergone operations, whether or not the patient has a medical record as to allergy or intubation difficulty, etc., physical examination, consultations to be performed by the involved branches and determining the method of anaesthesia (4,5).

Table 1. DSM-IV classification of Mentally Retarded patients according to their IQ level (1)

| | |
|----------------------|---|
| IQ of 100 and above | Normal |
| IQ is between 70-100 | Dull normal |
| IQ is between 50-70 | Mild mental retardation (trained) |
| IQ is between 40-50 | Moderate mental retardation (taught) |
| IQ is between 25-40 | Severe mental retardation (partially trained) |
| IQ below 25 | Heavy mental retardation (total care is required) |

These patients in question are generally syndromic ones. Therefore, in addition to MR, there are also comorbid (additional) diseases in these patients as part of these syndromes. This condition must be taken into consideration during the preoperative preparation period. Unfortunately, such a process could be rather challenging for these patients due to cooperation and communication disorders. The role of the family is of great importance in taking the medical history of these patients.

During the examination of the patient, the physician should be quite patient. Under the circumstances in which the physician's patience is challenged or there is a rather limited time, the systemic examination should be left to the consulting physicians and proper conditions and platforms should be observed.

In a MR-syndromic patient, the fact that cardiovascular and craniofacial abnormalities likely to cause difficulty in maintaining the airways/breathing, disorders in the endocrine and electrolyte balance, and musculoskeletal anomalies may occur must be kept in mind and an in-depth analysis and necessary consultations related to the involved branch should also be performed. Separately, it must also be kept in mind that in the diseases like Rett syndrome accompanied by MR, the risk of developing an intraoperative malignant hyperthermia is higher than the other patients, according to which the preoperative preparations must be carefully planned (6-9).

One of the most important parts of the pre-anaesthetic examination is the evaluation of the airways. In this patient population, the possibility to encounter such conditions as the worst Mallampati score that complicates intubation, thyromental distance, extension difficulty of the head and micrognathia is higher when compared with those in the normal patient population (3).

While determining the method of anaesthesia in the patients with MR, the type of the surgery, the mental retardation degree of the patient and the requests of the patient and patient relatives should be taken into consideration. In MR patients, it is hard to apply the regional anaesthetic techniques and ensure the adaptation of the patient in the course of the operation. For such reasons, selecting one of the general anaesthetic methods in these patients would be a far better approach (10).

Premedication provides serenity, mental comfort, euphoria and a slumber by eliminating the fear, anxiety and excitement in MR patients. Separately, the pressure of the undesired reflex actions, such as preoperative nausea, cardiac dysrhythmia and laryngospasm reduce the necessary anaesthetic dose by decreasing the metabolic activity and eventually allow for a calm waking up and comfortable recovery as well as minimizing the secretions in the respiratory tract and ensures avoiding toxic doses by diminishing the local anaesthetic requirement (5).

The preferable way in applying the drugs for premedication in these patients is the intake. In mentally retarded patients difficult to be persuaded to take drugs orally, the intramuscular way or intravenous ways could be used. (10).

For this purpose, hypnotic sedatives, tranquilizers and narcotic analgesic anxiolytics are used. Apart from this, antihistaminics are also benefited from in order to maintain a sedative effect. Antiemetics, anticholinergics, antacids and H₂ receptor blockers can also be used in premedication. One of the most applied and recommended agents used for the purpose of sedation is midazolam (0.1-0.2 mg/kg).

Another agent or agents like Ketamine can be added to Midazolam, as well. (11). In the patients unable to be convinced to take the drugs orally, neurolept analgesia agents like Ketamine (5-12 mg/kg) or haloperidol, droperidol (2-2.5 mg) can also be preferred (10).

In MR patients, in order to boost the adaptation of the patient to the hospital, premedication could be provided in the patient's home prior to visiting the hospital.

Chan et al. had practised premedication on a 36-year-old MR patient with Down and Treacher-Collins syndrome in his house to avoid any aggressive attitudes before being taken to the hospital. To that end, 10 mg of lorazepam and 1000 mg of ketamine were added into the milk to be given to the patient orally and hence, the sedation was ensured. Thus, the preparations for teeth and ear surgery to be performed in the hospital were made safely (12).

However, such sort of a practice is not that common since the follow-up would be rather difficult at home and as these patients may have comorbid/additional pathologies, as well, and the risks likely to be confronted may be more than expected.

Table 2. Some drug using in sedation (14-17). *nasal dose

| | Oral | Rectal | Intravenous (IV) | Intramuscular (IM) |
|--------------------------|----------|----------|------------------|--------------------|
| Midazolam (mg/kg) | 0.2-0.3* | 0.05-0.5 | 0.01-0.1 | 0.07-0.15 |
| Propofol (mg/kg) | - | - | 1.5-2.5 | - |
| Fentanyl (µg/kg) | - | - | 0.5-1.5 | 50-100 |
| Ketamine (mg/kg) | 3-10 | - | 0.2-0.8 | 2-4 |

We did not come across a similar practice in the literature, either.

In MR patients, apart from the operating room, anaesthetics are most frequently required in the magnetic resonance imaging process. Due to the fact that the procedure in the magnetic resonance imaging takes a long time and is rather noisy besides the fact that the patient has to totally stay motionless throughout the process, anaesthesia is a mandatory optional way in this respect.

Throughout the procedure, a deep sedation, a rapid recovery and providing patient security are essential. Different methods of sedation can be used to that end (Table 2). Performing a premedication on MR patients in a convenient atmosphere will boost the patient adaptation prior to being taken to the magnetic resonance imaging unit. In the centers where there are no recovery units, the whole team should be quite patient, and patient security must never be risked just to save time (13).

Peri-operative Preparation: Before the MR patients are brought into the operating room, difficult airway instruments, vascular accesses, the fluids to be transferred to the patient, including the induction drugs must all be ready along with all the preparations made. Hence, the unnecessary loss of time must be avoided prior to induction after the patient has been taken onto the operating table. The patient taken into the operating room is now sedated, peaceful or sleepy.

After the routine monitorization of the patient brought to the operating table (electrocardiography, non-invasive tension arterial and peripheral oxygen saturation), a preoxygenation with a mask is performed. The preoxygenation in particular is of great importance in these patients, since anaesthesia will allow for an extra period of time in order to cope with the airway problems likely to occur in the wake of induction.

Apart from the additional monitorization that may be required during the surgical procedure in MR patients, there is no other additional procedure to be performed. For the sake of avoiding the unnecessary use of agents during the intraoperative period, and again, for avoiding wakefulness and for the standardization of the anaesthetic depth, a bispectral index monitorization and follow-up can be performed.

However, in a study conducted by Ponnudurai et al. in 2010, it was put forward that no difference was observed in terms of the bispectral index among the groups during the intraoperative period (18).

IV method is preferred for induction in the patients accepting to have their sedation level vascular access established.

On the other hand, the inhalation anaesthetics can be preferred for induction in the patients whose vascular accesses cannot be established. Sevoflurane can be used to that end. Sevoflurane becomes prominent in induction when compared to the other inhalation agents due to its fast effects and nice aroma as well as having no irritant effect on the airways. For this purpose, 4-8% sevoflurane and 50% of oxygen/nitrogen mixture can be performed.

There are various options for the IV general anaesthetic agent following the induction through the inhalation anaesthetics. Among these are propofol (1.5-3 mg/kg), thiopental (4-7 mg/kg), ketamine (1-2mg/kg), and etomidate (0.3-0.5mg/kg).

It must always be kept in mind that of these agents, ketamine must be very carefully used in the patients with intracranial pressure increase, while thiopentalin must be carefully used in those in hypotensive shock, and etomidate must be very carefully used in the patients with a medical record of epileptic seizure (1,5).

As for the narcotic analgesics, there is no different condition in the MR patients compared to the other patient populations. Prior to preparing the muscle-relaxing agent, the fact that the openness of the patient's airways could be ensured must be verified and the difficult airway must be excluded. For this purpose, in the wake of the induction of the general anaesthetic agent, the Cormack Classification involving laryngoscopy and epiglottis and the inspection of the vocal cords must be rapidly performed. After having determined that there is no problem for intubation, muscle relaxants can be made (19).

Almost one fourth of the patients with mental retardation have a medical record of epileptic seizure (20). Due to the anti-epileptics used for a long time by the patients, the patients' susceptibility to the drugs metabolized due to the liver enzyme induction may have diminished.

For this reason, it must be particularly kept in mind that there may be a little nonsusceptibility to the non-depolarizing neuromuscular blocking agents of steroid structure, and the dose adjustment must be performed if required.

The depolarizing neuromuscular blocking agents must not be used in the case of muscular dystrophy that accompanies the MR patients more

frequently than the normal patient populations. Much care must be taken in the cannulation procedures required during the perioperative period.

In another study conducted by Sulemanji et al. (21). in 2009 on the cannulation of pediatric patients, where two patient populations- one with Down syndrome an one without Down syndrome- who had undergone a cardiac surgery were compared, it was stated that the arterial and venous cannulation in the population with the Down syndrome had been more challenging. In MR patients, the ultrasonography can be used for the purpose of noticing the anatomic variations during the central venous cannulation as well as the ease of procedures and avoidance of complications.

Recovery: In the recovery rooms, the MR patients pose a problem all by themselves. The limited number of health personnel in charge of these units and the challenge to take simultaneous care of more than one patient can cause some deficits in the necessary care and patience to be shown to these types of patients. The standard measurements/assessments that we use while evaluating the airway reflexes of the normal patients, such as opening the mouth and keeping it open, raising the head, and shaking hands, may not be used so often in this patient population in question. Instead, the patients must be kept under observation for longer periods of time and be referred to the involved service department to have their adequate muscle activities and the presence of their respiratory capacity observed. The patient should be re-evaluated by an experienced anaesthetist before leaving the recovery room (22).

Conclusion

In summary, since there may be several challenges/difficulties likely to be experienced at each stage of the mentally retarded patients' anaesthesia, far more care and patience is required. A pre-anaesthetic evaluation involving a physical examination in depth and a detailed questioning should be performed.

During the pre-medication period, a little amount of midazolam mixed with a proper drink can be used. The anaesthesia induction can be provided with the help of one of the inhalation anaesthetics, sevoflurane. Prior to applying the neuromuscle blocking agents, the airway opening must be maintained. In the presence of muscular dystrophies, the doses of neuromuscular blocking agents must be equalized.

Ultrasonography can be used in the course of the interventional procedures. The MR patients must be kept under observation in the recovery rooms for longer periods of time and must also be definitely re-evaluated by an experienced anaesthetist before being transferred to the service department

Conflict of Interest: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. Cagiran EY, Efeoglu C, Balcioglu T, KOCA H. Dental Treatment in Patients with Mental Retardation: A Retrospective Study. *Turkiye Klinikleri J Med Sci* 2011;31(4)
2. Koroglu E. Genellikle İlk Kez Bebeklik, Çocukluk ya da Ergenlik Döneminde Tanısı Konan Bozukluklar. *DSM_IV_TR Tani Ölçütleri* (2rd ed). Ankara: Hekimler Yayın Birliği, 2000
3. Tuzuner F. Preoperatif Hazırlık ve Ilac Tedavi Takiplerinde Prensipler. In: *Anestezi Yoğun Bakım Ağrı* (1rd ed). Ankara: MN Medikal ve Nobel Tıp Kitap Sarayı, 2010, pp 107-115
4. Butterworth J, Mackey D, Wasnick J. Preoperative Assessment, Premedication and Perioperative Documentation. In: *Clinical Anesthesiology* (5rd ed). North America: McGraw-Hill, 2013, pp 295-308
5. Kayhan Z. Anestezi ve Ameliyat Öncesi Değerlendirme ve Hazırlık. In: *Klinik Anestezi* (3rd ed). İstanbul: Logos Yayıncılık, 2007, pp 16-36
6. Yalcin S, Aydoğan H, Karahan MA et al. Williams Sendromlu Hastada Anestezik Yaklaşım: Olgu Sunumu. *Journal of Anesthesia* 2012; 20 (1): 48-50
7. Saritas T, Babacan K, Sarkılar G et al. Rett Sendromlu Bir Olguda Anestezik Yaklaşım. *Türk Anest Rean Der Dergisi* 2011; 39(3): 153-158
8. Özgül U, Begeç Z, Yuçel A et al. Cornelia de Lange Sendromlu İki Olguda Anestezi Yönetimimiz. *Journal of Anesthesia* 2012; 20 (2): 106-109
9. Gunduz C, Cogulu O, Ozkınay C et al. Investigation of Fragile X Syndrome in Idiopathic Mental Retardation. *EgeTıpDergisi* 2000; 39(2): 97-104
10. Paul G. Barash, Bruce F. Gullen, Robert K. Stoelting, et al. Preoperatif Değerlendirme ve Yönetim. In: *Klinik Anestezi* (5rd ed), 2007, p 477-501
11. Shah S, Shah S, Apuya J, Gopalakrishnan S et al. Combination of oral ketamine and midazolam as a premedication for a severely autistic and combative patient. *J Anesth* 2009; 23:126-128
12. Chan WP, Chilvers CR. Induction of Anesthesia in home. *Anaesth Intensive Care* 2002; 30:809-812
13. Tuzuner F. Ameliyathane Disinda Anestezi. In: *Anestezi Yoğun Bakım Ağrı* (1rd ed). Ankara: MN Medikal ve Nobel Tıp Kitap Sarayı, 2010, pp 1127-1136
14. Özlem CS. Nonopioid İntravenöz Anestezikler. In: *Temel Anestezi*. Yuksel K, Alkis N, Yorukoglu D, Alanoglu Z. Ankara: Gunes Tıp Kitapevi, 2012 pp 97-117
15. Başartelkin H. Opioidler. In: *Temel Anestezi*. Yuksel K, Alkis N, Yorukoglu D, Alanoglu Z. Ankara: Gunes Tıp Kitapevi, 2012 pp 87-95

16. Butterworth J, Mackey D, Wasnick J. Intravenous Anesthetics In: Clinical Anesthesiology (5rd ed). North America: McGraw-Hill, 2013, pp 175-188
17. Butterworth J, Mackey D, Wasnick J. Analgesic Agents In: Clinical Anesthesiology (5rd ed). North America: McGraw-Hill, 2013, pp 189-198
18. Ponnudurai RN, Clarke-Moore A, Ekulide I et al. A Prospective Study of Bispectral Index Scoring in Mentally Retarded Patients Receiving General Anesthesia. J Clin Anesth 2010; 22: 432-436 Cross Ref.
19. Butterworth J, Mackey D, Wasnick J. Airway Management In: Clinical Anesthesiology (5rd ed). North America: McGraw-Hill, 2013, pp 309-341
20. Ring H. Epilepsy in Intellectual Disabilities. ACNR 2013 September/October 13 (5): 14-15
21. Sulemanji DS, Donmez A, Akpek EA et al. Vascular Catheterization is Difficult in Infant with Down Syndrome. Acta Anaesthesiol Scand 2009; 53: 98-100 Cross Ref.
22. Tuzuner F. Postoperatif Erken Donem. In: Anestezi Yogun Bakim Agri (1rd ed). Ankara: MN Medikal ve Nobel Tip Kitap Sarayı, 2010, pp 1137-1152

Effect of acetaminofen versus lornoxicam administration on oxidative stress in rat hepatic and renal tissues

Mustafa Sancar Atac¹, Saban Cem Sezen², Mustafa Bilge³, Berrin Isik⁴, Mustafa Arslan^{4*}, Faruk Metin Comu⁵, Mustafa Kavutcu³, Dervis Yilmaz¹

Abstract

Background: The aim of study was to assess the oxidative status in rat hepatic and renal tissues after intraperitoneal administration of acetaminophen (AP) versus lornoxicam (L).

Materials and Methods: For this purpose 18 Wistar Albino rats were randomly divided into 3 groups; each group consists of 6 rats. Group Control (Group C) remain untreated, comprises healthy rats. Group AP received AP (100 mg kg⁻¹) and Group L received L (1.3 mg kg⁻¹) intraperitoneally. Oxidative status was evaluated by MDA, SOD, GST and CAT in hepatic and renal tissues. Furthermore histopathological evaluation was performed in both tissues.

Results: The lornoxicam received rats (Group L) showed significantly increased level of MDA and GST [(p=0.015), (p=0.048) respectively], decreased level of SOD (p=0.02) in liver tissue. Renal tissue MDA, SOD and GST activity and CAT levels were similar in groups [(p=0.168), (p=0.270), (p=0.686) respectively]. Histopathologically Group AP and Group L more damaged than in Group C. Hepatic injury was moderate level in two groups. Minimal injury was observed in group AP. Renal injury in group L more than the Group AP.

Conclusion: The results suggest that hepatotoxic effects of lornoxicam more than the AP while no remarkable difference nephrotoxicity.

Key words: Oxidative Stress, Acetaminophen, Lornoxicam, Rat, Hepatic, Renal

Introduction

Nonsteroidal anti-inflammatory drug (NSAID)'s and acetaminophen (AP) have been used as an analgesic (1,2). Acetaminophen is normally metabolized in the liver and kidney by cytochrome P450 enzymes which differ somewhat in character between the liver and kidney.

In spite of no toxicity is observed with therapeutic doses of AP both clinical and experimental studies revealed that even much lower doses can produce renal damage (2). Nephrotoxicity is a major complication of AP exerts acute and chronic nephrotoxic effects. AP toxicity is dependent on the bioactivation by CYT enzymes to N-acetyl p-benzoquinoneimine (NAPQI) depletion of GSH, adduct formation to target proteins and oxidative stress. Although the sequence of biochemical changes associated with AP toxicity is believed to be proportional to the degree of covalent binding of AP to target proteins.

The cytotoxicity of NAPQI can be dependent on its metabolism via one-electron reduction followed by reoxidation. This redox cycle reaction can reduce molecular oxygen to superoxide anion with a consequent formation of hydrogen peroxide and hydroxyl radical. In addition to reactive oxygen species, AP toxicity can increase reactive nitrogen species generation, and these oxidative species can induce lipid peroxidation, protein oxidation, and DNA fragmentation; hence are a potential cause of cell death. Renal tissue is the secondary while liver the first target organ of AP toxicity. Oxidative stress is an important component of the AP hepatotoxicity (2,3). AP produces necrosis of the centrilobular cells of the liver and often causes liver failure when taken in overdose (3). Non-steroidal anti-inflammatory drug may cause to reduce the renal blood flow, glomerular filtration rate, retention of water and sodium and may also cause hyperkalemia (4) the administration of single dose of lornoxicam on rats in our previous

Received: 23-03-2015, Accepted 07-04-2015, Available Online 01-06-2015

¹Gazi University, Dept. of Oral and Maxillofacial Surgery, Ankara, Turkey

²Kirikkale University, Faculty of Medicine, Dept. of Histology and Embryology, Kirikkale, Turkey

³Gazi University, Faculty of Medicine, Dept. of Medical Biochemistry, Ankara, Turkey,

⁴Gazi University, Faculty of Medicine, Dept. of Anesthesiology and Reanimation, Ankara, Turkey,

⁵Kirikkale University, Faculty of Medicine, Dept. of Physiology, Kirikkale, Turkey

*Corresponding Author: Mustafa Arslan E-mail: mustarslan@gmail.com

study, revealed that liver and renal blood flow was decreased but this was not statistically significant. On the other hand paracetamol did not cause any alterations (5).

Recent reports described liver injuries in association with cyclooxygenase ranging from acute liver failure to varying degree of transient cholestatic liver injury (6).

Lornoxicam (chlorotenoxicam), a NSAID drug of the oxicam class with analgesic, anti-inflammatory and antioxidant properties, is available in oral and parenteral formulations (7). Anti-inflammatory and analgesic properties of lornoxicam have greater potency (8).

Many other drugs in addition to AP such as L are known to induce oxidative stress and the cause side effects during their metabolism in the liver. Although side effects of lornoxicam have been well documented in previous studies (9,10), comparison with lornoxicam and AP has not been investigated to the best of our knowledge. The purpose of this study was to determine the effects of intraperitoneally administered single dose AP versus L on oxidative stress in rat renal and hepatic tissue in terms of MDA, SOD, GST activity, CAT levels and tissue histopathology

Material and method

Animals and study Design

This study was conducted in the Physiology laboratory of Kırıkkale University upon the consent of the Experimental Animals Ethics Committee of Kırıkkale University. The experiments were conducted in accordance with ethical guidelines for investigations in laboratory animals.

In the study, 18 male Wistar Albino Rats 250-300 gr in weight, raised under the same environmental conditions, were used. The rats were kept under 20-21 °C at cycles of 12-hour daylight and 12-hour darkness and had free access to food until 2 hours before the anaesthesia procedure.

Three groups of rats were formed as the study and control groups. Randomized 6 rats were grouped as control and no surgical procedure was performed (Group C, n=6). The study groups were administered lornoxicam (Xefo® Abi İbrahim İlaç San ve Tic A.Ş, İstanbul, Turkey) 1.3 mg kg⁻¹ intraperitoneally (Group L) and another study groups were administered i.v. paracetamol (Perfalgan® Bristol-Myers Squibb Pharmaceuticals Ltd, UK) 100 mg kg⁻¹ intraperitoneally (Group AP).

Thirty minutes after lornoxicam and iv paracetamol administration, the rats were weighed and then anaesthetized with ketamine (Ketalar®100 mg

mL-1, Pfizer, İstanbul, Turkey), and the euthanasia via intraabdominal blood uptake was performed.

Histopathological evaluation

The semi-qualitative evaluation technique, which was used by Abdel-Wahhab et al (11) and Sen et al (10) was employed for the evaluation of structural changes in control and experimental groups. The slides for control and experimental groups were examined and assigned semi-qualitatively for severity of changes using scores on a scale of none (-), mild (+), moderate (++) and severe (+++) damage.

Biochemical Analysis

The liver and renal tissues were first washed with cold deionized water to discard blood contamination and then homogenized in a homogenizator. Measurements on cell content require an initial preparation of the tissues. The preparation procedure may involve grinding of the tissue in a ground glass tissue blender using a rotor driven by a simple electric motor. The homogenizator as a tissue blender similar to the typical kitchen blender is used to emulsify and pulverize the tissue (Heidolph Instruments GMBH&CO KGDiax 900 Germany®) at 1000 U for about 3 min. After centrifugation at 10 000 g for about 60 min, the upper clear layer was taken.

MDA levels were determined using the method of Van Ye et al. (12) based on the reaction of MDA with thiobarbituric acid (TBA). In the TBA test reaction, MDA and TBA react in acid pH to form a pink pigment with an absorption maximum at 532 nm. Arbitrary values obtained were compared with a series of standard solutions (1,1,3,3-tetraethoxypropane). Results were expressed as nmol/mg protein.

Part of the homogenate was extracted in ethanol/chloroform mixture (5/3 v/v) to discard the lipid fraction, which caused interferences in the activity measurements of T-SOD, CAT and GST activities. After centrifugation at 10.000 x g for 60 min, the upper clear layer was removed and used for the T-SOD, CAT, GST analyses.

In the upper clear layer, T-SOD, CAT and GST enzyme activities were measured as described Durak, et al (13), Aebi (14) and Habig et al (15), methods respectively. One unit of SOD activity was defined as the enzyme protein amount causing 50% inhibition in NBTH2 reduction rate and result were expressed in U/mg protein. The CAT activity method is based on the measurement of absorbance decrease due to H₂O₂ consumption at 240 nm. The GST activity method is based on the measurement of absorbance changes at 340 nm due to formation of GSH-CDNB complex. PON1 activity toward

paraoxon was assessed by adding samples to 2 mL Tris/HCl buffer containing CaCl₂, paraoxon (O,O-diethyl-O-p-nitrophenylphosphate), and NaCl. Rate of generation of p-nitrophenol was determined at 405 nm and 25 °C in a spectrophotometer.

Increases in absorbance were recorded at 30-sec intervals during 5 min after 30 sec of initial pre-incubation. Enzymatic activity was calculated from molar extinction coefficient (17,000 L/mol.cm).

Statistical analysis

All variables were expressed as median and range. Differences between groups were evaluated by Kruskal–Wallis variance analysis followed by a post-hoc Mann–Whitney U-test. P-values <0.05 were considered statistically significant. All data were entered into and processed by SPSS 20.0 for Windows statistical package

Results

In present study hepatic tissue MDA, SOD, GST enzyme activity was showed significant difference in groups [(p=0.015), (p=0.002), (p=0.048) respectively]. MDA and GST enzyme activity is higher in Group L than in Group AP [(p=0.014), (p=0.048) respectively], SOD activity was lowest in Group AP, and lower in Group L than in Group C [(p=0.011), (p=0.003), (Table 1)]. But CAT and GST enzyme level in hepatic tissue was similar to that of in Group AP and Group L (Table 1).

Renal tissue MDA, SOD, GST activity and CAT levels were similar in groups [(p=0.168), (p=0.270), (p=0.673), (p=0.686) respectively (Table 2)].

Histopathological results

Liver

In the control group, the histopathological evaluation of the liver tissue showed hepatocytes in a radial pattern extending along vena centralis and a normal architecture of sinusoids.

Hepatocyte cordons had a homogenous distribution pattern. Congestion in vena centralis, sinusoidal dilatation and minimal cellular changes were observed. In addition mild non-specific inflammatory cells and mild dilatation of sinusoids were apparent in portal area (Figure 1, Table 3).

Histological sections obtained from lornoxicam showed a significant hepatic degeneration, sinusoidal dilatation, picnotic and hyperchromatic cells, focal necrosis sites and mononuclear cell infiltration, Kuppfer cell hyperplasia, inflammation, congestion and ballooning of peripheral hepatocytes.

Necrotic and apoptotic appearance, degenerative changes, vasocongestion and bleeding areas were evident/apparent on hepatocytes around vena centralis. (Figure 2a, 2b, Table 3).

In the paracetamol group the alignment of the sinusoids were irregular. The size of the hepatocytes and hepatocyte cordons around vena centralis were similar with the control group. Vacuoles were noted around sinusoids adjacent to paranchimal cells.

Congestion in vena centralis and dilatation of sinusoids were observed as well as minimal cellular changes. In some areas mild nonspecific inflammatory cells, mild dilatation of sinusoids and mild hydrophilic degeneration of hepatocytes were identified. There were basophilic areas with an irregular structures in the cytoplasm of hepatocytes. (Figure 3, Table 3).

Kidney

The semislides obtained from the control group revealed no abnormal changes from the normal histological structures. (Figure 4).

In the lornoxicam group the most noticeable findings were the vacualizations in proximal tubular epithelium and the reduction in brush border. Tubules comprising vacuoles in basal localization and transparent tubules were also remarkable.

Browman distance and enlargement and congestion in blood vessels between tubules were observed. Abundant increase in mesangial matrix, glomerular hypertrophy, thickening of basement membrane were not detected. Dilated tubules were mostly seen in distal tubules Bleeding areas, inflammatory cells, disseminated tubular cells were also observed. Glucogenic vacuolization (Armani-Ebstein lesions), degeneration and detachment of brush border of tubular epithelium, particles in tubular epithelial cell cytoplasm were detected in proximal tubules. (Figure 5).

In the paracetamol group loss of brush border and microvillus and focal vacualizations were identified. Infiltrations, vasocongestion, asymmetrical proximal tubules, bleeding areas, thickened basal membrane and shortening of brush border were also observed.

Dilatation of tubules was rare. Tubular degeneration was seen in some certain tubulus and was not common. The tubules which doesn't have a certain vacuolization had a normal structure. Narrowing in browmann distance, increase in mesangial matrix and glomerular hypertrophy were not observed. (Figure 6).

Table 1. Oxidative status parameters in rat hepatic tissue [Mean±SD]

| | Group C (n=6) | Group AP (n=6) | Group L (n=6) | P** |
|--------------------------|------------------|-------------------|------------------|-------|
| MDA (nmol/mg prot) | 2,28±1,00 | 4,35±2,33 | 6,05±2,33* | 0,015 |
| SOD(U/mg protein) | 383,35±91,27 | 238,63±58,48* | 258,89±42,14* | 0,002 |
| GST (Liver) (IU/mg prot) | 17,75±5,15 | 25,73±8,69* | 26,73±4,58* | 0,048 |
| CAT (IU/mg prot) | 5920,67±1700,42 | 6463,86±1932,57 | 7458,86±1010,15 | 0,234 |

P**: p< 0.05 (with Kruskal Wallis test)

*p<0.05: Comparison with Group C


Table 2. Oxidative status parameters in rat kidney tissues [Mean±SD]

| | Group C (n=6) | Group AP (n=6) | Group L (n=6) | P** |
|--------------------|------------------|-------------------|------------------|-------|
| MDA (nmol/mg prot) | 7,82±2,58 | 9,43±1,66 | 10,42±2,88 | 0,168 |
| SOD(U/mg protein) | 95,48±40,03 | 62,94±32,87 | 82,40±33,16 | 0,270 |
| GST (IU/mg prot) | 1,14±0,27 | 1,00±0,31 | 1,07±0,25 | 0,673 |

P**: Kruskal Wallis test

Table 3. Comparison of histological changes in rat liver by means of semi-qualitative evaluation

| | Group C (n=6) | Group AP (n=6) | Group L (n=6) |
|--|------------------|-------------------|------------------|
| Hepatocyte degeneration | - | + | +++ |
| Sinusoidal dilatation | + | ++ | ++ |
| Pycnotic nucleus | - | + | ++ |
| Cell pre necrosis | - | + | ++ |
| MN cellular infiltration in the parenchyme | + | ++ | +++ |

**Figure 1:** A slide of liver tissue obtained from the control group (vc: vena centralis, * dilated sinusoids Toluidine blue.x40)




Figure 2a: Hepatocyte and vena centralis degeneration in lornoxicam group)(centrolobular damage)sinusoidal dilatation, (*) Picnotic and hyperchromatic nüclei(←) Vacuolar degeneration (^)(Toluidine blue.x20)




Figure 2b: Necrotic and apoptotic appearance of hepatocytes around vena centralis in the semislides obtained from the lornoxicam group (nec), Kupffer cell hyperplasia (k), Picnotic and hyperchromatic nuclei (←), sinusoidal dilatation (*)Toluidine blue.x40)




Figure 3: (Hydrophilic degeneration of hepatocytes around vena centralis in acetaminophen group, necrotic and apoptotic appearance, Kupffer cell hyperplasia(k), picnotic and hyperchromatic nuclei(←), sinusoidal dilatation(*)Toluidine blue.x40)




Figure 4: (Proximal and distal tubules of kidney tissue in control group MC: malpighian corpuscle, B: Bowman's gap, pa:parietal fascia, po: podocyte nucleus, e:endothelium, me: mesangial cell, mv: brush border of the proximal tubule, JGA: juxta glomerular apparatus) (Toluidine blue.x40)




Figure 5: Malpighi corpuscle in the semislide of lornoxicam group, proximal and distal tubules. PT: Proximal tubule, DT: Distal tubule, B: Bowman's gap, pa: squamous epithelium of parietal fascia, e: endothelium, MD: macula densa and JG: juxtaglomerular cells, conj: congestion, inf: inflammation, vacuole: diffuse proximal tubule vacuolization (increase in the number and size of vacuoles) (Toluidine blue.x40)




Figure 6: Renal cortex including malpighi corpuscle, proximal and distal tubules are shown in the semislide obtained from acetaminophen group. G: glomerulus, PT: proximal tubule, DT: distal tubule, B: Bowman's gap, pa: squamous epithelium of parietal fascia, c: congestion, inf: inflammation, vacuole: vacuolization of focal proximal tubule) (Toluidine blue.x40)

Discussion

Acetaminophen-Liver

Acetaminophen is the most commonly used medication worldwide because of its efficacy and safety profile. There have been several reports in the literature that suggest that acetaminophen leads to liver damage and failure (16-18). It is important to note that the doses leading to liver failure are within therapeutic range (19).

Acetaminophen produces hepatic necrosis due to the chemical reactions and interactions among hepatocytes. Acetaminophen is regarded as hepatotoxin (20). The toxicity occurs by a complex sequence of events. These include prothetin, oxidative stress, calcium imbalance, changes in transcription ways, signals leading to inflammation and apoptosis. (21)

The studies on lipid peroxidation, antioxidant enzymes (glutathione peroxidase, superoxide dismutase and catalase) have been found to be of great importance in the assessment of liver damage (22).

Oxidative stress is reported to constitute a major mechanism in the pathogenesis of PCM-induced liver and adrenal damage in experimental animals (23).

Oxidative damage has been reported as a mechanism contributing to acetaminophen toxicity (24). Koçak et al (24) reported that there was no statistically significant difference in terms of lipid peroxidation levels under low doses of acetaminophen (5, 10 ve 20 mg/kg) in comparison with control group. A slight increase was found in MDA levels in high dose of acetaminophen administration (100, 200 ve 500 mg/kg) in comparison with control and low dose groups. However this finding was reported not to be statistically significant. SOD values were also found to be similar.

Koçak et al. (24) concluded that intraperitoneal administration of acetaminophen (5, 10 ve 20 mg/kg) had no acute toxicity on liver.

Lores et al (25) found no significant change in SOD efficiency following 375 mg/kg acetaminophen administration, while a 40-53% decrease was reported in GSH-Px efficacy.

In an experimental study by Ranivce et al a significant increase was reported in GPx levels following paracetamol use (26).

Lipid peroxidation in acute acetaminophen toxicity is controversial (27). In the present study a mild increase in MDA levels were observed, whereas there was no significant difference among groups. Our results correlate with the findings of Knight et al (28), who reported no significant change following 300 mg/kg paracetamol use. Paracetamol-treated animals

showed alterations in the antioxidant status of the tissues, which is manifested as an abnormal histopathology like cloudy swelling, centrilobular fatty changes, steatosis, fatty vacuolization and individual hepatocytic necrosis of hepatic cells (26).

Koçak et al. (24) demonstrated mononuclear cell infiltration around portal vein, picnotic and hyperchromatic cells and granular and vacuolar degeneration in hepatocytes following administration of 100 mg/kg acetaminophen use.

In the present study vacuolar structures were in the parenchymal cells adjacent to the sinusoids. Congestion of vena centralis, sinusoidal dilatation and minimal cellular changes were also evident in some areas. Mild non-specific inflammatory cells on portal areas, mild dilatation of sinusoids and mild hydrophilic degeneration of hepatocytes were observed.

Acetaminophen-Kidney

Renal failure secondary to analgesic and antipyretic drug use has been frequently reported in the literature. However renal failure following paracetamol and flurbiprophen administration in therapeutic doses has rarely been reported (17,18).

Gökçeoğlu et al (19) reported four cases of acute tubulointerstitial nephritis. The findings of the biopsy specimen obtained from the first case revealed moderate interstitial inflammation, lenfocyte infiltration, moderate interstiyel fibrosis, tubular necrosis, mild tubular atrophy. Mild interstitial inflammation, lenfocyte and eosinofil infiltration, mild interstitial fibrozis, tubular atrophy were reported for the second biopsy specimen of the second patient. Immunofluorescent evaluation was reported to be negative for both cases.

In these two cases the paracetamol dosage was in therapeutic limits and the usage period was short. However the medical history of the patients included antibiotic usage combined with paracetamol use (19).

In the present study the slides of paracetamol group revealed infiltration centers, vasocongestion, asymmetrical proximal tubules, bleeding areas, thickened basement membrane and shortening of brush border. Tubular dilatation was rare. New tubulus formations were present. Tubular degeneration was observed at some tubules and was not common. The tubules presenting cloudy vacuolization were in normal architecture. Narrowing of Browman distance, increase in mesangial matrix and glomerular hypertrophy were not observed.

Linares et al. (29) reported that, during kidney injury, superoxide radicals are generated at the site of damage and modulate SOD and CAT, resulting in the loss of activity and accumulation of superoxide

radical, which damages kidney. SOD and CAT are the most important enzymes involved in ameliorating the effects of oxygen metabolism.

Availability of paracetamol as an over counter medication alone and in combination with other prescription creates a situation that may lead to exposure to excessive quantities of the drug (30). Insensitive individuals, such as persons with renal insufficiency, therapeutic doses of paracetamol have also been implicated in kidney damage (31).

In the present study Significant increases were detected in SOD and CAT levels in rat kidney tissues. However there was no significant difference among groups.

Lornoxicam-Liver

Kathleen and Michael (32) reported adverse effects with NASIDs used in dog and rats which include gastrointestinal bleeding, ulceration and platelet dysfunction nephrotoxicity, hepatotoxicity. Which results in fulminant hepatic failure and acute tubular necrosis (10).

As a possible mechanism, production of cytochrome p450-mediated metabolic activation, uncoupling of oxidative phosphorylation, mitochondrial permeability transition and generation of reactive oxygen species have been suggested (33).

Sen et al. (10) who also reported that CAT and GSH levels increased in LOR-treated group compared to those in control groups.

Hummdi et al. (34) reported that hepatocytes degradation and necrosis surrounding the portal area as well as lost their nuclei with cirrhosis of the space around the portal vein and increase the thickness of the artery and the expansion of the lymph duct also observed.

LeBail et al. (35) investigations consistent with the current study, they attribute hypertrophy of Kupffer's cells to the defense activity of these cells in the phagocytosis of red blood cells infected and cellular debris. The hypertrophy of endothelial lining cells due to their important role in inflammatory reactions against injuries and damages tissue.

In the current study histological sections obtained from lornoxicam showed a significant hepatic degeneration, sinusoidal dilatation, picnotic and hyperchromatic cells, focal necrosis sites and mononuclear cell infiltration, Kupffer cell hyperplasia, inflammation, congestion and ballooning of peripheral hepatocytes. Necrotic and apoptotic appearance, degenerative changes, vasocongestion and bleeding areas were apparent on hepatocytes around vena centralis.

Lornoxicam-Kidney

Rabab et al. (36) reported that the kidney showed congestion in tauff of glomeruli associated with the degeneration in the lining epithelium of the renal tubules. Focal inflammatory cell infiltration between the tubules with therapeutic dose.

Radhofer–Welte and Rabasseda (37) studied the clinico pathological changes of the kidney by effect of lornoxicam as renal papillary necrosis but the kidney associated changes were not completely reversible during recovery period. Aydin et al. (38) determined that the lesion of the kidney varied from degeneration and epithelial cell necrosis in epithelial lining of some tubules with mononuclear cell infiltration in the interstitium, eosinophilic secretion in the tubules lumen.

In the current study the lornoxicam group showed vacuolisations and decrease in brush border of proximal tubulus epithelium. Tubules comprising vacuolar in multiple sizes and transparent tubules were remarkable. Enlargement of Bowman distance and blood vessels and congestion of blood vessels were significant. Tubular dilatation was generally observed in distal tubules. Bleeding areas, inflammatory cells, and diffuse tubule cells were also observed

Conclusion

These results suggest that lornoxicam may cause unfavorable pathological changes in the liver and kidney more than acetaminophen, and that further studies are needed to identify the nephrotoxic and hepatotoxic effect in patient with renal or hepatic deficiency.

Lornoxicam and acetaminophen were cause to mild to moderate reversible injury in rat hepatic or renal tissue. Acetaminophen or lornoxicam induced oxidative stress in rat hepatic tissue more than in renal tissue. Further studies are required to understand toxic effect of acetaminophen or lornoxicam renal or hepatic deficiency patients

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, et al. 2001 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. *Am J Emerg Med* 2002; 20: 391-452.

2. Waters E, Wang JH, Redmond HP, et al. Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. *Am J Physiol Gastrointest Liver Physiol* 2001; 280: 1274-1279.
3. Noriega GO, Ossola JO, Tomaro ML, Batlle AM. Effect of acetaminophen on heme metabolism in rat liver. *Int J Biochem Cell Biol* 2000; 32: 983-991.
4. Gambaro G, Perazella MA. Adverse renal effects of antiinflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. *J Int Med* 2003; 253: 643-52.
5. Arslan M, Comu FM, Isik B, Atac MS, Yilmaz D. The evaluation of effects of lornoxicam on blood flow and erythrocyte deformability in comparison with i.v. paracetamol in rats. *Bratisl Med J* 2012; 113: 211-213.
6. Andrzej P, Monika W, Agnieszka S, Wejeiech G, Patrycja LK, Jerzy M. NSAID acute liver failure-A case Report. *J. Chromatogr. B. Analyte. technol. Biomed. cif. sci*, 2011; 879:573-578.
7. Turner P, Johnston A. Clinical pharmacokinetic studies with lornoxicam. *Postgrad. Med. J.* 1990; 66: 28-9.
8. Bianchi M, Panerai AE. Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hind paw hyperalgesia induced by formalin injection in rat tail. *Pharmacol Res* 2002; 45: 101-105.
9. Pohlmeier-Esch G, Mehdi N, Clarke D, Radhofer-Welte S. Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rats. *Food Chem. Toxicol.* 1997; 35: 909-922.
10. Sen S, Doger FK, Sen S, Aydin ON, Karul A, Dost T. The protective effect of nitroglycerin on gastrointestinal and renal side effects of lornoxicam in rats. *Eur J Pharmacol* 2006; 541: 191-7.
11. Abdel-Wahhab MA, Nada SA, Arbid MS. Ochratoxicosis: Prevention of developmental toxicity by L-methionine in rats. *Journal of applied toxicology. J Appl Toxicol* 1999; 19: 7-12.
12. Van Ye TM, Roza AM, Pieper GM, Henderson J Jr, Johnson JP, Adams MB. Inhibition of intestinal lipid peroxidation does not minimize morphological damage. *J Surg Res* 1993; 55:553-558.
13. Durak I, Canbolat O, Kavutcu M, Öztürk HS, Yurtarslanı Z. Activities of total, cytoplasmic and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patient with lung cancer. *J Clin Lab Anal* 1996; 10: 17-20.
14. Aebi H. Catalase. In: H.U. Bergmeyer (Ed): *Methods of Enzymatic Analysis*, Academic Press, New York and London, 1974; pp.673-677.
15. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. *J Biol Chem* 1974; 249:7130-9.
16. John CM, Shukla R, Jones CA. Using NSAID in volume depleted children can precipitate acute renal failure. *Arch Dis Child* 2007; 92: 524-526
17. Onay OS, Erçoban HS, Bayrakçı US, Melek E, Cengiz N, Baskin E. Acute, reversible nonoliguric renal failure in two children associated with analgesic-antipyretic drugs. *Pediatric Emergency Care* 2009; 25 (4): 263-266
18. Banal F, Lecoules S, Carmoi T, Thomas L, Bonnefoy S, Bechade D, Desrame J, Algayres JP. Acute renal insufficiency after flurbiprofen treatment in a patient treated with angiotensin converting enzyme inhibitor. *Rev Med Interne* 2008; 29: 593-595
19. Gökçeoğlu Uslu A, Doğan ÇS, Çomak E, Akkaya B, Koyun M, Akman S. Acute tubulointerstitial nephritis: presentation of four cases. *Turk Neph Dial Transpl* 2013; 22: 106-110.
20. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol* 2009; 20: 629-637
21. Krause I, Cleper R, Einstein B, Davidovitis M. Acute renal failure, associated with non-steroidal anti-inflammatory drugs in healthy children. *Pediatr Nephrol* 2005; 20: 1295-1298
22. Duh PD. Antioxidant activity of Burdock, its scavenging effect on free radical and active oxygen. *J Am Oil Chem Soc* 1998; 75:455-458.
23. Basma K, Ramadanand Mona F. Schaalán. The renoprotective effect of clover flowers honey on paracetamol-induced nephrotoxicity in adult male albino rats. *Life Science Journal* 2011; 8:589-596.
24. Koçak A, Gökçimen A, Yılmaz N, Vural H. Evaluation of the effect of acetaminophen at different doses on hepatic nitric oxide synthase enzyme by using immunohistochemical and biochemical methods. *Nobel Med* 2011; 7: 88-95.
25. Lores Arnaiz S, Llesuy S, Cutrín JC, Boveris A. Oxidative stress by acute acetaminophen administration in mouse liver. *Free Radic Biol Med* 1995; 19: 303-310.
26. Sheeba Rani M, Emmanuel S, Sreekanth MR, Ignacimuthu S. Evaluation of in vivo antioxidant and hepatoprotective activity of cassia occidentalis linn, against paracetamol-induced liver toxicity in rats. *Int J Pharmacy Pharm Sci* 2010; 2:67-70.
27. Wendel A, Feuerstein S, Konz KH. Acute paracetamol intoxication of starved mice leads to lipid peroxidation in vivo. *Biochem Pharmacol* 1979; 28: 2051-2055.
28. Knight TR, Fariss MW, Farhood A, Jaeschke H. Role of lipid peroxidation as a mechanism of liver injury after acetaminophen overdose in mice. *Toxicol Sci* 2003; 76: 229-236.
29. Linares MV, Belles M, Albina ML, Sirvent JJ, Sanchez DJ. Assessment of the pro-oxidant activity of uranium in kidney and testis of rats. *Toxicol Lett* 2006; 167:152-61.
30. Shayiq RM, Roberts DW, Rothstein K, Snawder JE, Benson W, Ma X et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. *Hepatology* 1999; 29: 451-463.

31. Stern S, Bruno M, Hennig G, Horton R, Roberts J, Cohen S. Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice. 1. Enhancement of acetaminophen nephrotoxicity by acetaminophen–cysteine. *Toxicol Appl Pharmacol* 2005; 202: 151-9.
32. Kathleen AS, Michael SL. Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs. *J Vet Intern Med* 2006;20:1291-1296.
33. Chung H, Kim HJ, Jang KS, Kim M, Yang J, et al. comprehensive analysis of differential gene expression profiles on diclofenac-induced acute mouse liver injury and recovery. *Toxicology Letters* 2006;166: 77-87.
34. Hummdi LA, Habashi SA. Histological and ultrastructure studies on the liver changes induced by xefo drug (lornoxicam) of adult female mice. *Foreign Agricultural Relations (FAR), Egypt*, 29th Nov – 1st Dec 2010: 551– 575
35. LeBail B, Bioulac-sage P, Senuila R, et al. Fine structure of hepatic sinusoid cells in disease. *J Electron Microscop Tech* 1990;14:257-282.
36. Rabab R El-zoghby, Mona F. Biochemical and histopathological changes of lornoxicam in albino rats. *Proc. of the 5th Animal Wealth Research Conf. in the Middle East & North Africa*. 2012: 254- 271.
37. Radhofer–Welte S, Rabasseda X. Lornoxicam, a new potent NSAID with an improved tolerability profile. *Drugs Today* 2000; 36:55-76.
38. Aydin G, Gokcimen A, Oncu M, Cicek E, Karahan N, Gokalp O. Histopathological changes in liver and renal tissues induced by different doses of diclofenac sodium in rats. *Turk J Vet Anim Science* 2003;(27) :1131-1142

Coronary Artery Bypass surgery and sexual function

Mehmet Bilgehan Yuksel¹, Ilhan Gecit², Ayhan Karakose³, Necip Pirincci², Mustafa Gunes²,
Cemalettin Aydin⁴, Mehmet Kaba²

Abstract

Objectives: To evaluate the influences of coronary artery by-pass surgery (CABS) on sexual function(SF) and the comorbidities on the impact of CABS on SF.

Methods: The data of 112 patients who underwent CABS and interviewed by full form of IIEF questionnaire before and 6 months after CABS were retrospectively evaluated. We specifically analyzed and compared the preoperative and postoperative (PAP) IIEF questionnaire(IQ) results to determine the influences of CABS on SF. Furthermore, we separately analyzed the same PAP data in diabetic, hypertensive and both diabetic and hypertensive subgroups and compared the data in each group to find possible influences of the comorbidities on the impact of CABS on SF.

Results: The mean age was 61,7±9,1. The number of patients without erectile dysfunction(ED) increased from 3(%2.6) to 7(%6.2), with severe and moderate ED decreased from 85(%75.9) to 33(%29.4), with mild ED increased from 24(%21.4) to 72(%64.2) after CABS, which revealed the severity of ED declined in overall and ED completely improved in some patients after CABS. The total IIEF, erectile function (EF), intercourse satisfaction, orgasmic function and sexual desire scores significantly increased after CABS(P=0,000). Although OS(Overall Satisfaction) had an increase, no statistically significant alteration was found(P= 0,04). The SF most improved in both diabetic and hypertensive group, it was least affected in diabetic group.

Conclusions: CABS had positive impacts on EF and almost all domains of SF. While the lonely presence of diabetes did not significantly affect the impact of CABS on SF, the SF most improved in both diabetic and hypertensive cases after CABS.

Key words: Comorbidities; coronary artery by-pass surgery; sexual function

Introduction

The most common cause of death in the world is cardiovascular disease (CVD) (1,2). Sexual dysfunction (SD) is common in patients with CVD. The reported prevalence of erectile dysfunction (ED) shows an increase from %46 in men with coronary artery disease (CAD) to 84% in men with congestive heart failure (2-4). Age, medical treatments, and cardiovascular risk factors such as hypertension, diabetes mellitus, and dyslipidaemia have been shown to be contributing to impaired sexual function (SF) (5-7). Cardiac surgeries are among the most stressful operations for the patients, and coronary artery bypass surgery (CABS) is one of the most frequent surgical procedure actually used for the treatment of CAD (8,9). Although most of the elderly people remain sexually active and there is an established relation between CAD and male SD, studies analyzing the SF following CABS are limited.

When some studies stated that preoperative erectile function (EF) appeared to be the best predictor of postoperative EF in patients who will undergo CABS, one study suggested that the conventional on-pump CABS surgery could significantly impact SF (9-11). However, resumption of SF is one of the important factors of psychosocial recovery after CABS (12).

The aim of this study was evaluating the SF before and after CABS in patients with CAD, and determining the incidence and types of sexual problems and the possible alterations in SF after CABS in relation with some comorbidities by using full form of International Index of Erectile Function (IIEF) questionnaire, in an effort to obtain data for counselling and rehabilitation of future patients

Material and method

The data of 112 patients who underwent CABS were retrospectively evaluated. The data of patients who underwent elective CABS, were preoperatively and postoperatively interviewed by using the full form of IIEF questionnaire, had no previous cardiac surgery except for cardiac catheterization and had stable partners with regular intercourse were included in the study. The data of patients with the features that could alter SF such as renal failure, thyroid disease, chronic liver disease, previous pelvic and genitourinary surgeries, and who had previous diagnosis and medical or surgical treatment of ED were excluded from the study.

The patients were interviewed by full form of IIEF questionnaire previous to CABS. This questionnaire consists of 15 questions to evaluate the subgroups of sexual function including total IIEF score, erectile function (EF), orgasmic function (OF), sexual desire (SD), intercourse satisfaction (IS) and overall satisfaction (OS). Scoring the IIEF domain of erectile function provides the classification of each patient as having no (26–30), mild (17–25), moderate (11–16) or severe (0–10) ED. As a result of this evaluation, we have determined the preoperative status of EF and other subgroups of SF in IIEF questionnaire. At 6th month's control, the questionnaire was completed by all patients again and the same data demonstrating postoperative status were also collected. By using preoperative and postoperative data, we specifically analyzed and compared the preoperative and postoperative IIEF questionnaire results with the aim of finding the incidence and severity of ED, determining the possible alterations in all subgroups of SF in IIEF questionnaire related to CABS, and showing the possible influences of CABS on SF.

The descriptive data were also evaluated in the sample. This data included age, body mass index, the comorbidities of diabetes mellitus (DM), hypertension (HT) and both (DM+HT), the severity of vascular disease, alcohol, smoking habit and medical treatments. The patients were grouped into 3 subgroups according to the concomitant comorbidities, such as diabetic (group 1), hypertensive (group 2) and both diabetic and hypertensive (group 3) subgroups. We separately analyzed the same preoperative and postoperative IIEF data in 3 subgroups and compared the data in each group with the aim of finding possible influences of the comorbidities on the impact of CABS on SF results of IIEF questionnaire.

Statistical analysis

All data were reviewed retrospectively. Data are expressed as Mean±SD. The categorical variables were presented as percentage (%). Analytical tests including independent

Student's *T*-tests, Mann Whitney U test and Wilcoxon test were used for comparing the

preoperative and postoperative data and evaluating the correlations between the data, as appropriate. A *P* value <0, 05 was considered significant. SPSS version 16.0 was used for the analyses.

Results

The mean age was 61.7±9.1 years. The sample included 41(36.6%) diabetic, 50 (44.64%) hypertensive and 28 (25%) diabetic and hypertensive patients. 76 (67.8%) patients were with hyperlipidemia. One vessel disease, 2 vessel disease, 3 vessel disease and multivessel disease was determined in 10(8.92%), 33(29.46%), 52(46.42%) and 17(15.17%) patients, respectively. The mean ejection fraction was 58%±17.4. The demographic features of patients were clearly demonstrated in table 1.

Table 1. The demonstration of demographic features of patients

| | |
|------------------------------|---------------|
| n | (112) |
| Mean age | 61.7±9.1 |
| DM | 41 (36.6%) |
| Hypertension | 50 (44.64%) |
| DM + Hypertension | 28 (25%) |
| Hyperlipidemia | 76 (67.85%) |
| Smoking | 85 (75.89%) |
| Family history | 59 (52.67%) |
| One vessel disease | 10 (8.92%) |
| Two vessel disease | 33 (29.46%) |
| Three vessel disease | 52 (46.42%) |
| Multivessel disease | 17 (15.17%) |
| Mean ejection fraction | 58% (SD 17.4) |
| Beta blocker medication | 83 (74.10%) |
| CCB medication | 7 (6.25%) |
| ACE inhibitor medication | 46 (41.07%) |
| AT2 blocker medication | 8 (7.04%) |
| Statin medication | 89 (79.46%) |
| Diuretic medication | 13 (11.60%) |
| Mean body mass index | 28 (SD 3.77) |
| DM: Diabetes mellitus | |
| CCB: Calcium channel blocker | |

The analysis of preoperative and postoperative IIEF results showed that severe ED was preoperatively present in 1(0.89%) patient, and it was increased to 8 (7.14%) at 6th month postoperatively. While 84 (75) patients had moderate ED preoperatively, it decreased to 25 (22.32%) at 6th month control after the surgery. However, 24(21.42%) patients were with mild ED preoperatively, this result increased to 72(64.28%) postoperatively. The number of patients without ED increased from 3 (2.6%) to 7 (6.2%). The preoperative and postoperative results of ED were clearly seen in table 2.

The evaluation of IIEF data regarding all subgroups of sexual function in IIEF questionnaire in overall revealed that total IIEF scores significantly increased after the operation (*P*=0.000). In addition, both of the IIEF scores of EF, IS, OF and SD also significantly increased (*P*=0.000 in all).

Table 2: The demonstration of pre and postoperative status of erectile dysfunction in the sample. (1., 2., 3., 4., 5. and 15. questions in IIEF -15 questionnaire evaluates the erectile function.)

| Severity of ED | Preoperative Erectile Function | Postoperative Erectile Function |
|--------------------------------|--------------------------------|---------------------------------|
| Severe ED (IIEF score 6-10) | 1 (0.89%) | 88 (7.14%) |
| Moderate ED (IIEF score 11-16) | 84 (75%) | 25 (22.32%) |
| Mild ED (IIEF score 17-25) | 24 (21.42%) | 72 (64.28%) |
| No ED (IIEF score 26-30) | 3 (2.6%) | 7 (6.2%) |

No significant alteration was occurred in the IIEF score of OS postoperatively (P=0.04). The analysis and comparison of IIEF results in the subgroups of sexual function in IIEF questionnaire in overall was demonstrated in table 3.

Table 3. The comparison of pre and postoperative IIEF scores in overall.

| IIEF subgroups | Mean | Mean Diff. | P value |
|--------------------------|-------------|------------|---------|
| Preop total IIEF | 37,47±5,07 | | |
| Postop total IIEF | 47,16±11,51 | 9,69 | 0,000 |
| Preop EF | 15,34±2,24 | | |
| PostopEF | 18,08±5,39 | 2,74 | 0,000 |
| Preop IS | 9,15±1,21 | | |
| Postop IS | 10,45±2,54 | 1,3 | 0,000 |
| Preop OF | 3,78±1,13 | | |
| Postop OF | 6,86±2,17 | 3,08 | 0,000 |
| Preop SD | 4,26±0,77 | | |
| Postop SD | 5,49±1,99 | 1,23 | 0,000 |
| Preop OS | 4,95±1,68 | | |
| Postop OS | 5,53±2,21 | 0,58 | 0,040 |

N=112
 EF: erectile function,
 IS: intercourse satisfaction,
 OF: orgasmic function,
 SD: sexual desire
 OS: overall satisfaction

The analysis of IIEF data in 3 subgroups of the sample regarding the comorbidities declared different results. In group 1, it was seen that there were no statistically significant differences between preoperative and postoperative scores of total IIEF (P=0.226), EF (P=0.328), IS(P=0.161), and SD (P=0.668). While OF score significantly increased from 3.70±1.10 to 6.17±2.34 (P=0.000), OS significantly decreased from 5.34±1.66 to 4.09±1.82 after the operation (P=0.003). In group 2, the scores of total IIEF, EF, IS, OF and SD significantly increased (P=0.000 in all). Although an increase from 4.80±1.69 to 5.82±1.90 was also seen in terms of OS score, it was not found statistically significant (P=0.06). In group 3, total IIEF and EF scores significantly increased from 35.82±6.56 to 56.42±5.97 and from 14.67±2.95 to 22.07±3.37, respectively (P=0.000 in all).

Furthermore, a significant improvement was also seen in other subgroups of sexual function in IIEF questionnaire including IS, OF, SD and OS (P=0.000 in all). The analysis and comparison of preoperative and postoperative IIEF data in 3 subgroups of the sample regarding the comorbidities were shown in table 4

Table 4: Pre and postoperative IIEF scores in 3 subgroups, regarding to the comorbidities.

| | Mean | Mean Diff. | p value |
|---------------------|-------------|------------|---------|
| Group 1 n=41 | | | |
| Preop IIEF | 38,04±3,75 | | |
| Postop IIEF | 40,19±11,47 | 2,25 | 0,226 |
| Preop EF | 15,65±1,65 | | |
| PostopEF | 14,85±5,11 | -0,8 | 0,328 |
| Preop IS | 9,14±0,96 | | |
| Postop IS | 9,85±2,88 | 0,71 | 0,161 |
| Preop OF | 3,70±1,10 | | |
| Postop OF | 6,17±2,34 | 2,47 | 0,000 |
| Preop SD | 4,39±0,86 | | |
| Postop SD | 4,29±1,45 | -0,1 | 0,668 |
| Preop OS | 5,34±1,66 | | |
| Postop OS | 4,09±1,82 | -1,25 | 0,003 |
| Group 2 n=50 | | | |
| Preop IIEF | 37,72±4,73 | | |
| Postop IIEF | 49,14±8,93 | 11,42 | 0,000 |
| Preop EF | 15,34±2,07 | | |
| PostopEF | 19,26±4,28 | 3,92 | 0,000 |
| Preop IS | 9,32±0,76 | | |
| Postop IS | 10,68±2,27 | 1,36 | 0,000 |
| Preop OF | 4,04±1,12 | | |
| Postop OF | 7,08±1,98 | 3,04 | 0,000 |
| Preop SD | 4,16±0,65 | | |
| Postop SD | 5,68±1,99 | 1,52 | 0,000 |
| Preop OS | 4,80±1,69 | | |
| Postop OS | 5,82±1,90 | 1,02 | 0,060 |
| Group 3 n=28 | | | |
| Preop IIEF | 35,82±6,56 | | |
| Postop IIEF | 56,42±5,97 | 20,6 | 0,000 |
| Preop EF | 14,67±2,95 | | |
| PostopEF | 22,07±3,37 | 7,4 | 0,000 |
| Preop IS | 8,85±1,89 | | |
| Postop IS | 11,10±1,42 | 2,25 | 0,000 |
| Preop OF | 3,35±0,98 | | |
| Postop OF | 7,42±2,13 | 4,07 | 0,000 |
| Preop SD | 4,25±0,75 | | |
| Postop SD | 6,67±1,76 | 2,42 | 0,000 |
| Preop OS | 4,60±1,49 | | |
| Postop OS | 7,25±1,95 | 2,65 | 0,000 |

EF: erectile function,
 IS: intercourse satisfaction,
 OF: orgasmic function,
 SD: sexual desire
 OS: overall satisfaction

Discussion

CABS is known to cause inflammatory response that is primarily associated with low blood pressure, temperature changes, leukocytosis and tissue edema and can lead to end-organ dysfunction, which may affect the SF (2,13,14). The current technical and technological improvements have rendered CABS more safe, reducing to acceptable levels the surgical risk even in older cases (2,15). Although most of the elderly people are sexually active and there is an established relation between CAD and male SD, studies analyzing the SF following CABS are limited. The most common sexual problems in patients with CAD are faced with include reduced libido, avoidance of sexual activity, and ED (16). When some studies stated that preoperative EF appeared to be the best predictor of postoperative EF in patients who will undergo CABS, one study suggested that the conventional on-pump CABS surgery could significantly impact SF (10,11).

In the present study, we aimed to evaluate the preoperative and postoperative status of SF in patients with CAD, to determine the incidence and types of sexual problems and the possible alterations in SF after CABS in relation with some comorbidities by using the full form of IIEF questionnaire. ED is defined as the inability to achieve an erection in order to maintain satisfactory intercourse. The prevalence of ED in general population is 19–52% (2,17). Atherosclerosis is the most common cause of ED, and the patients with CAD are commonly together with ED that occurs as a result of some potential mechanisms (2,18). ED has significant influences on quality of life. There were only a few studies in literature, which evaluated EF retrospectively before and after CABS, regarding to changes in EF after CABS (19,20). In our study we evaluated EF before and after the surgery. It was found that the number of patients without ED increased 3(%2.6) to 7(%6.2). However, while total account of severe and moderate ED decreased from 85(%75.9) to 33(%29.4), the number of patients with mild ED increased from 24(%21.4) to 72(%64.2). It was clearly seen that the severity of ED declined in overall and also ED completely improved in some patients (n=4) after the surgery. Therefore, we supposed that CABS had positive impacts on EF. In the literature, one study revealed that CABS may have a significant impact on EF (10,21). Nevertheless, some reports declared that CABS does not provide a net gain in SF (10,11). It should be kept in mind that ED may be early marker of CAD, and must prompt every physician to evaluate the patient for CAD (18). Although some previous reports in the literature commonly used the short form of IIEF questionnaire (IIEF-5) and analyzed only EF and/or had commonly no sufficient follow-up period, we used the full form of IIEF questionnaire and also evaluated all sexual components of the sample before and 6 months after CABS. Thus, we could analyses the alterations in other components of sexual function

in IIEF questionnaire related to the CABS. The previous literature showed that CABS influenced SF and resumption of sexual activity is an important factor for recovery. In a study, it was found that after the diagnosis of a cardiac disorder or a cardiac intervention, %25 lost their SF completely, %25 of patients had normal SF, and %50 had a decreased SF (22). The previous literature determined that a considerable improvement in comparison to the patients' status before CABS and one study declared that the most common sign of patients' recovery after cardiac surgery is resumption of their social and sexual activity (2,23).

In our study, the evaluation of IIEF data regarding all subgroups of SF in IIEF questionnaire revealed that total IIEF score and IIEF scores of EF, IS, OF and SD significantly increased after the operation (P= 0,000 in all). Although an increase were also seen in terms of OS, no statistically significant alteration was found (P= 0,04). The improvement of the majority of subgroups of SF in IIEF questionnaire showed that CABS had positive impacts on SF of patients with CAD. Vascular disorders are one of the organic causes of SF so it is not surprising that the patients with CAD have SD. The association between ED and cardiovascular risk factors has been previously reported by several authors (2,24-27). Both ED and CAD share the same risk factors including aging, diabetes mellitus, hypertension, hyperlipidemia and smoking (19,27-29). Although there are some reports addressing the predictive factors of SF following CABS; they did not evaluate the impacts of each vascular RFs on sexual function after CABS (10,11). In our study, the sample were divided in 3 subgroups according to the comorbidities, including diabetic (group 1), hypertensive (group 2) and both diabetic and hypertensive (group 3) subgroups. The preoperative and postoperative IIEF data were separately determined in 3 subgroups. The comparison of preoperative and postoperative IIEF results in each group with the aim of finding possible influences of the comorbidities on the impact of CABS on sexual function was performed. This analysis revealed different results in each group. In group 1, it was seen that there were no statistically significant differences between preoperative and postoperative scores of total IIEF, EF, IS, and SD. Nevertheless, OS score significantly decreased, while OF score significantly increased in diabetic patients after CABS. In the guidance of these results, it was concluded that CABS had no significant effects on sexual function in diabetic patients with CAD. Nevertheless, while total IIEF, EF, IS, OF and SD scores significantly increased in group 2. These results showed that a significant improvement was occurred in almost all scores of the parameters in hypertensive patients after CABS. Furthermore, all scores of the subgroups of sexual function in IIEF questionnaire significantly improved in group 3 after CABS. In overall, these results revealed that while the sexual function most improved

in both diabetic and hypertensive patients, it was least affected in only diabetic patients after CABS.

Conclusion

The determination of the decline in the severity of ED in overall and the complete improvement of ED in some patients after CABS revealed that CABS had positive impacts on EF in patients with CAD. Furthermore, the demonstration of a significant improvement in the majority of subgroups of SF in IIEF questionnaire was concluded that CABS had also an encompassing positive impact on almost all domains of sexual function in patients with CAD. On the other hand, the analysis of possible influences of the comorbidities on the impact of CABS on sexual function showed that while the lonely presence of diabetes mellitus did not significantly affected the impact of CABS on sexual function, the sexual function most improved in both diabetic and hypertensive cases after CABS. We supposed that these results need to be confirmed by prospective and randomized trials in greater series.

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

- Lukkarinen H, Lukkarinen O. Sexual satisfaction among patients after coronary bypass surgery or percutaneous transluminal angioplasty: Eight-year follow-up. *Heart Lung*. 2007;36:262-269.
- Kim ED, Owen RC1, White GS, Elkelay OO, Rahnema CD. Endovascular treatment of vasculogenic erectile dysfunction. *Asian Journal of Andrology* 2015;17:40-43
- Foroutan SK, Rajabi M. Erectile dysfunction in men with angiographically documented coronary artery disease. *Urology*. 2007; 4: 28–32,
- Schwarz ER, Kapur V, Bionat S, et al. The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. *International Journal of Impotence Research*. 2008; 20: 85–91,
- Kendirici M, Nowfar S, Hellstrom WJG. The impact of vascular risk factors on erectile function, *Drugs of Today*. 2005; 41; 1: 65–74
- Jackson G. The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadism, *European Urology*, 2006; 50(3): 426–427.
- Montorsi P, Ravagnani PM, Galli S et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial, *European Heart Journal*, 2006; 27(22): 2632–2639.
- Mohamed OA, Bennett CJ, Roaiah MF, Helmy T, Mahran A, Hamed HA. The impact of on-pump coronary artery bypass surgery vs. off-pump coronary artery bypass surgery on sexual function. *J Sex Med* 2009;6:1081–1089
- Schmitz C, Weinreich S, Schneider R et al. Offpump versus on-pump coronary artery bypass: Can OPCAB reduce neurologic injury? *Heart Surg Forum*. 2003; 6:127–30.
- Gueglio G, Chamas G, Ruda Vega P, Garcia Merletti P, Domenech A, Damia O. Erectile function after myocardial revascularization surgery. Analysis of 30 cases. *Arch Esp Urol*. 2002;55:57–62.
- Hizli F, Isler B, Gunes Z, Ozatik MA, Berkmen F. What is the best predictor of postoperative erectile function in patients who will undergo coronary artery bypass surgery? *Int Urol Nephrol*. 2007;39:909–912
- MacVary KT. Sexual Dysfunction. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Larry Jameson J, et al. *Harrison's Principles of Internal Medicine*. 17th Ed. New York: McGraw Hill. 2008; 296.
- Bulcroft K, O'Connor M. The importance of the dating relationships on quality of life for older persons. *Family Relations J Appl Family Child Studies*. 1986; 35(3):197-401.
- Buvat J, Buvat-Herbaut M, Lamaire A, Marcolin G, Quittelier E. Recent developments in the clinical assessment and diagnosis of erectile dysfunction. *Annu Rev Sex Res*. 1990;1:265-299
- ZiabakhshTabary S, Mokhtari-Esbuie F, Fazli M. Evaluations of erectile dysfunction before and after on-pump coronary artery bypass graft surgery. *Caspian J Intern Med* 2014; 5(4): 209-212
- Grahan I. Rehabilitation of the Patient with Coronary Heart Disease. In: Fuster V, ORourke RA, Walsh RA, Poole-Wilson P. *Hurst's The Heart*. 12th Ed. New York: Mc Graw Hill; 2007:1543.
- Braun M, Wassner G, Klotz T et al. Epidemiology of erectile dysfunction: results of the "Cologne Male Survey". *Int J Impot Res*. 2000; 12: 305–311.
- Schwartz BG, Kloner RA How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. *Int J Impot Res*. 2009; 21: 327-335.
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. "Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study," *J Urol*. 1994;151:54–61.
- Pournaghash-Tehrani S, Etemadi S. ED and quality of life in CABG patients: an intervention study using PRECEDE-PROCEED educational program. *Int J Impot Res*. 2014 Jan;26(1):16-9.
- Heaton JP, Evans H, Adams MA, Smith K, Morales A. Coronary arteries bypass graft surgery and its impact on erectile function: A preliminary prospective study. *Int J Impot Res*;1996;8:35–9.
- Debusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. *Am J Cardiol*. 2000;86:175-181.
- Bernardo A. Sexuality in patients with coronary disease and heart failure. *Herz*. 2001; 26: 353-359.

24. Gerber RE, Vita JA, Ganz P, Wager CG, Araujo AB, Rosen RC, Kupelian V. Association of peripheral microvascular dysfunction and erectile dysfunction. *J Urol.* 2015;193(2):612-7.
25. Parazzini F, Menchini Fabris F, Bortolotti A et al. Frequency and determinants of erectile dysfunction in Italy. *Eur Urol.* 2000;37:43-49
26. Chew KK, Earle CM, Stuckey BGA et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. *Int J Impot Res.* 2000;12:41-45
27. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. *Prev Med.* 2000;30:328-338
28. Ledda A Cigarette smoking, hypertension and erectile dysfunction. *Curr Med Res Opin.* 2000;16:13-16
29. Moore CS, Grant MD, Zink TA et al. Erectile dysfunction, vascular risk, and cognitive performance in late middle age. *Psychol Aging.* 2014 Mar;29(1):163-72

Retrospective analysis of deep sedation in pediatric population for endoscopic procedures: adverse events and outcomes

Berrin Isik¹, Volkan Sivgin¹, Mustafa Arslan^{1*}, Seyfi Kartal¹, Yusuf Unal¹, Mehmet Akcabay¹

Abstract

Background: Upper gastrointestinal endoscopy (E) and colonoscopy (C) procedures are not well tolerated in pediatric population. General anesthesia or sedation applied during gastroendoscopic procedures. This study is done to review our sedation practice and to evaluate the clinical effectiveness and side effects of an anaesthesiologist administered deep sedation for gastroendoscopic procedures outside the operating room.

Methods: After Institutional Review Board Approval, the charts of all children who underwent endoscopic procedure at the outpatient endoscopy suite under sedation, (Jan 2011- December 2011) were reviewed retrospectively.

Results: Deep sedation was used in 301 procedures, which 255 were endoscopic and 23 were colonoscopic procedures. Twenty-three children had both procedures performed in one session. Demographic details: Age [year, mean]: 10,1±5,1, Gender (M/F): 152/149, Body weight [kg, (mean±SD)]: 35.7±18.7. Severe bradycardia with oxygen desaturation was recorded in two patients. All procedures were carried out successfully. Emergence delirium was seen in only one patient who was the substance user. No significant side effect derived from intervention was observed during the procedures, except one case (perforation of the colon).

Conclusion: Deep sedation applied by anaesthesiologist found to be adequately safe and appropriate for children during gastroendoscopic procedures

Key words: Child, Complication, Sedation, Ambulatory Anesthesia

Introduction

In paediatric patients, sedation or sedo-analgesia procedures are required when there is anxiety, fear of medical procedures, behavioural impairment and pain. Upper gastrointestinal endoscopy (E) and colonoscopy (C) frequently performed to diagnose and treat a wide range of gastrointestinal problems. These procedures are not well tolerated in paediatric population. For those reason endoscopic procedures under sedation or general anaesthesia is preferred option.

The aims and objectives of providing care during sedation or general anaesthesia on children are amnesia, motionless, safety, early discharge, and cost effective care. But sedation or general anaesthesia are not complication free applications. Furthermore endoscopic procedures are frequently performed outside the operating room (1-5). Significant complications during such procedures have been reported (6).

There exists a great variation in anaesthesia practice for paediatric endoscopy. Increased awareness of the complications associated with sedation during GI endoscopic procedures in children,

the institution of modern monitoring modalities to identify these complications, and the involvement of the anaesthesiologists in looking after these children in, or outside, the operating room is optimal for the safety of these patients (1-8).

We aim to present adverse events and outcomes at endoscopic procedures under deep sedation applied by the anaesthesiologist in paediatric population

Material and method

This study was approved by the institutional review board at Gazi University Faculty of Medicine. The anesthesia database at our hospital during January 2011-December 2011 interval was searched for all patients less than 19 years of age referred for gastro endoscopic procedures under deep sedation. All interventions were performed by same team of the pediatric gastroenterologist. All sedation was given by a staff anaesthesiologist. Following demographic and clinical data were obtained:

age, gender, weight, ASA classification, time of endoscopy procedure, oxygen delivery method, doses of the anesthetics, and hemodynamic variables during sedation, complications, and any therapeutic interventions performed.

Procedural and resuscitative equipment of a size and type appropriate for pediatric use was readily available during procedures. There were no premedication's prior to the procedure.

For all patients EKG, non-invasive blood pressure and SpO₂ monitoring were used. All patients received supplemental O₂ at 2-3 l/min through nasal cannula. Sedation level was sustained with sedation agent as University of Michigan Sedation Scale (UMSS) (9) scores (3,4).

Post-Anesthetic Discharge Scoring System (PADSS) was used to discharge of the patients from endoscopy suit, and total score ≥ 9 was considered for discharge (10). The effectiveness of intravenous sedation was defined as successful completion of the procedure. Sedation-related complications were defined as desaturation (oxygen saturation $< 94\%$), bradycardia (heart rate $< 20\%$ than initial values), need for supplemental oxygen (above baseline supplementation). Intervention related complications were recorded too.

Statistical analysis

The statistical analyses were performed with SPSS 17.0 software program and $p < 0.05$ was considered statistically significant. Data were presented as mean value \pm standard deviation (SD), (Min-Max), n, (%).

Kolmogorov-Smirnov test was performed for the measurable parameters in order to determine whether the range is normal. Parametric values were evaluated with one-way ANOVA with Bonferroni adjustment. Numerically equality be achieved and non-parametric values were studied with Kruskal-Wallis test and the differences were evaluated with Mann-Whitney U test. HR and SpO₂ parameters were analysed using repeated-measures analysis of variance (ANOVA), with Bonferroni's adjustment. Complication and/or side effects were compared using Chi-square and Fisher's exact tests

Results

Three hundred and one procedures (n=255 E, n=23 C, n=23 E+C) were performed on 301 children (Table 1). Supplemental oxygen was given via nasal cannula, ambu or endotracheal intubation (Table 2). Doses of used anesthetics, anesthetic agents or combinations in terms of groups, quantity of the used anesthetic agents and procedure time were shown in Table 3, Table 4 and Table 5 (respectively). Time dependent heart rate and SpO₂ variables were shown in Figure 1 and 2.

Complication and/or side effects in terms of E, C, and E+C groups were shown in Table 6. Significant desaturation was recorded in seven patients (lowest SpO₂ values were 55%). Endoscopic intervention was stopped and the children were ventilated 100% O₂ by ambu mask (n=5) or endotracheal tube (n=2) than SpO₂ values were normalized. The procedures were then completed uneventfully. No significant side effect derived from intervention was observed during the procedures except one patient (perforation of the colon) and then endotracheal intubation was attempted. Colonic perforation case was carried out to the operation room for urgent surgical operation. Except this case all procedures were carried out successfully. Severe agitation and delirium was seen during recovery period in one patient who was the substance addicted

Discussion

This retrospective study demonstrates clinical effectiveness and side effects of deep sedation applied by the anesthesiologist for pediatric gastro endoscopic procedures.

The aims and objectives of providing sedation on children for endoscopic procedures are: allowing the children to tolerate the unpleasant procedures, remaining motionless, amnesia, preventing complications, ensuring safety, ensuring early discharge from the facility to home providing high quality and cost effective care. This also requires careful consideration of the patient, the endoscopy facility, and the variables of the procedure itself. Patient factors include age, weight, concurrent diseases, airway assessment, pre-procedure anxiety, and pain tolerance. Procedure variables include the amount of anticipated discomfort, the duration of examination, and how invasive the procedure will be. Although GI endoscopy is generally considered safe, the procedure does have a potential for complications.

For pediatric gastroendoscopic procedures general anesthesia or sedation are applied in anesthesia practice. It is important to recognize that most pediatric sedation are deep and risk and adverse events occur more than adults (1-5).

In our work; parents of the patients were informed of and agree to the administration of anesthesia, including discussion of its benefits, risks, and limitations and possible alternatives. Patient's historic details just like; diseases of major organ systems, snoring, stridor, sleep apnea, allergies, prior adverse reaction to drugs, current medications, time of and type of last oral intake, alcohol, or substance use are obtained by direct questions. Furthermore physical examination (measurement of vital signs, determination of baseline level of consciousness, and assessment of the cardiopulmonary system was performed.

Table 1. Demographic properties and operation data [Mean±SD (Min-Max), n]

| | |
|---|----------------------|
| Number of the patient (n) | 301 |
| Gender (Male/Female) | 152/149 |
| Age (Year) | 10,16±5,19 (0,25-18) |
| Weight (kg) | 35,74±18,72 (5-83) |
| ASA (I/II) | 265/36 |
| Time of endoscopy procedure (minute) | 20,36±12,75 (5-75) |

Table 2. Oxygene delivery method [n (%)]

| Devices | n, (%) |
|--------------------------------|---------------|
| Nasal canula | 294 (98) |
| Ambu | 5 (1,4) |
| Endotracheal entubation | 2 (0,6) |

Table 3. Doses of anesthetics [n, Mean±SD (Min-Max)]

| IV Pharmacologic agents | n | Mean±SD (Min-Max) |
|--------------------------------|----------|--------------------------|
| Propofol (mg) | 261 | 112,17±60,31 (10-310) |
| Midazolam (mg) | 284 | 0,91±0,24 (0,5-2) |
| Ketamine (mg) | 144 | 19,58±13,19 (5-70) |
| Fentanyl (µg) | 2 | 37,50±17,68 (25-50) |

Table 4. Used anesthetic agents or combinations [n, (%)]

| Used anesthetic agents | E (n=255) | C (n=23) | E+C (n=23) |
|-----------------------------------|----------------------|---------------------|-----------------------|
| Propofol | 15 | - | - |
| Midazolam+Propofol | 126 | 11 | 4 |
| Midazolam+Ketamin | 35 | 1 | 3 |
| Midazolam+Ketamin+Propofol | 77 | 11 | 16 |
| Sevoflurane | 2 | - | - |

Table 5. Quantity of the used anesthetic agents and procedure time [Mean±SD (Min-Max)]

| | E (n=255) | C (n=23) | E+C (n=23) | p** |
|-----------------------------|--------------------------|---------------------------|---|------------|
| Propofol (mg) | 104,29±53,26 (10-270) | 167,73±80,23* (40-300) | 137,25±71,85* (20-310) | <0,0001 |
| Midazolam (mg) | 0,91±0,25 (1-2) | 0,91±0,20 (0,5-1) | 0,94±0,23 (0,5-1,5) | 0,844 |
| Ketamin(mg) | 18,28±12,29 (5-70) | 15,58±10,32 (5-45) | 30,00±15,55 ^{&*} , (5-60) | 0,002 |
| Fentanil (µg) | - | 50 | 25 | - |
| Procedure time (min) | 10,06±6,13 (5-45) | 37,17±13,38* (10-75) | 50,87±10,52*,& (30-75) | <0,0001 |

p** p<0.05 Kruskal-Wallis Test

*p<0.05 Comparison with Group E

&p<0.05 Comparison with Group C

Table 6. Complication and/or side effects in terms of E, C and EC groups [n (%)]

| | E (n=255) | C (n=23) | E+C (n=23) | p |
|-----------------------------|----------------------|---------------------|-----------------------|--------------------------------|
| Nausea/vomiting | 2 (0,8) | - | - | X ² =0,663, p=0,718 |
| Desaturation (94≤) | 5 (2) | 1(4,5) | 1 (4,5) | X ² =0,829, p=0,661 |
| Bradycardia | 1 (0,4) | - | - | - |
| Respiratory distress | 2 (0,8) | 1(4,5) | - | X ² =2,024, p=0,364 |
| Allergy | 2 (0,8) | 1(4,5) | - | - |
| Colon perforation | - | 1(4,5) | - | X ² =2,024, p=0,364 |




Figure 1. Time dependent heart beat rate in terms of groups




Figure 2. Time dependent SpO2 values in terms of groups

Thakkar et al (4) found that, the younger the age group, the higher the ASA class and intravenous (IV) sedation as risk factors for developing complications. Selection of patients according to this risk stratification may help to prevent or reduce complications associated with the procedure (5). In our series all the patients were in ASA I-II class.

There are no absolute guidelines as to timing of fasting before administration of sedation because of the absence of supporting data with regard to a direct relationship between duration of fasting and risk of pulmonary aspiration. The ASA guidelines recommend that patients should not consume fluids or solid foods for a sufficient period of time so as to permit adequate gastric emptying (11, 12). In our clinic; patients were prevented from taking clear fluid, breast milk, light meal or heavy meal orally for 2, 4, 6 to 8 hours (respectively). No patient had pulmonary aspiration related complication in our series.

Monitoring is essential during sedation and recovery period. Pulse oximetry is a valuable tool to pick up oxygen desaturation but may not adequately reflect hypoventilation, apnea, impending hemodynamic instability, or vasoconstrictive shock. In particular, patients may be well saturated with oxygen and still experience significant CO₂ retention. Capnography has emerged as a noninvasive way of measuring patient ventilation that may be especially useful in patients undergoing deeper levels of sedation (11-14). Malviya et al (7) picked up desaturation in 5.5% of patients and achieved a reduction in bad

outcomes. Hypoxemia secondary to depressed respiratory activity is the most important risk factor for near misses and death during sedation for children undergoing procedures. Early detection may be valuable in avoiding morbidity and mortality in pediatric sedation procedures. In our series patients were observed closely. Desaturation was observed in 7 patients. Although SpO₂ was monitored EtCO₂ was not monitored causes of technical failure.

Oxygen was administered by nasal cannula in all of our patients. This practice is a matter of debate because it could affect the timely detection of hypoventilation (13,14). On the other hand, the ASA guidelines recommend supplemental oxygen during sedation, and many authors follow this recommendation (11,12).

In our clinic oropharyngeal topical anesthesia just before endoscopy was not used because topical anesthetic agents have been associated with serious adverse effects (aspiration, anaphylactoid reactions) (15).

There aren't exact consensuses about anesthetic management of children for endoscopic procedures, and general anesthesia, sedation, or non-sedation (awake) methods are using 1-3. In recent years, 4 levels of sedation were identified, which stretch along a continuum without clear boundaries: minimal sedation or anxiolysis, moderate sedation, deep sedation, and general anesthesia. To date, these levels of sedation have been defined by a patient's response to verbal, light tactile, or painful stimuli, although they are generally also associated with physiologic changes in patient vital signs. Deep sedation is a drug-induced depression of consciousness, during which patients cannot be easily aroused but respond purposefully to repeated or painful stimulation. The ability to maintain ventilator function may be impaired. Patients may require assistance in maintaining a patent airway, and spontaneous ventilation may be inadequate. Cardiovascular function is usually maintained (16). In our series deep sedation level [UMSS scores 3-4 (9)] was intended.

Gastroscopy is a widely-used method for detecting upper gastrointestinal diseases. However, hypoxias, elevations of blood pressure and heart rate have repeatedly been demonstrated during gastroscopy (1-5). These potentially harmful side-effects are sometimes life-threatening, particularly for patients with accompanying disease. Although it has been shown that sedation during gastroscopy helps to prevent the increase in blood pressure and heart rate, hypoxia still remains a potential risk following administration of sedation Administration of sedation incurs additional medical expenditure and risks. The most common serious and life-threatening complications related to sedation are respirator in etiology. Of these, the most serious is aspiration because its consequences may be impossible to correct

or prevent once substantial aspiration has occurred. Even minor episodes of aspiration may result in prolonged coughing, bronchospasm, or pulmonary infections. Thus, avoidance of pulmonary aspiration is critical for safe endoscopic practice. These events are related to the depth of sedation and may result from suppression of respiratory drive in the central nervous system or from airway collapse that occurs with sedation. Cardiovascular complications are less commonly life threatening during endoscopy, and, when life threatening, they most often follow a period of inadequate ventilation and hypoxemia. Nevertheless, the physiologic response to sedation and the physical stress of endoscopy is quite variable. Individual patients have a susceptibility to vagally mediated bradycardia and hypotension that can be precipitated by stretching the sigmoid mesentery during passage of a colonoscope. In other patients, marked tachycardia may develop if the procedure is started when they are inadequately sedated, particularly during upper endoscopic procedures. Hypertension is seen commonly during endoscopic procedures. Although hypotension and hypertension during endoscopy very rarely result in permanent complications, they occasionally reach levels for which corrective action is appropriate. Atrial or ventricular arrhythmias are rarely precipitated by sedation or stress of the procedure (4,5,7,12,17,18). In works of Deenadayalu et al (19) a worldwide multicenter safety review of more than 521,000 patients was conducted. Mask ventilation rates were 0.4:1000 patients for upper endoscopy and 0.1:1000 patients for colonoscopy. Endotracheal intubations, neurologic injuries, and death occurred in 4, 1, and 3 patients, respectively. The 3 deaths occurred in patients with significant comorbid illnesses such as widely metastatic malignancy and polysubstance abuse.

Although gastrointestinal endoscopy occasionally is a safe procedure, significant complication can occur as a result of instrumentation, such as bleeding, perforation and infection. In our series rather than seventeen cases (patients with nausea/vomiting, desaturation, severe bradycardia, respiratory distress, colon perforation, allergy) vital parameters were stable all procedures long. All procedures except one (colonic perforation) carried out successfully.

Sedation is applied by nonanesthesiologist too. Motas et al (20) in a prospective study of pediatric population undergoing sedation by non-anesthesiologists for various procedures reported failure to achieve sedation in 12%-28% using BIS or the UMSS respectively as a monitor of sedation. Malviya et al (7), in another prospective study involving 1140 children sedated by a non-anesthesiologist for various procedures, reported a 20.1% incidence of adverse events. These included inadequate sedation, low oxygen saturation, airway

obstruction, apnea needing bag mask ventilation, and excitement and agitation. Lightdale et al (21) prospectively reviewed more than 2300 endoscopic procedures and reported agitation, respiratory events, incomplete procedures, hemorrhage and perforation as adverse events. Agitation was significantly associated with endoscopist-administered sedation. Mamula et al (22) in a retrospective review of conscious sedation in children also reported approximately 20% incidence of non-life threatening adverse events. Levis et al (23) reported a 20% incidence of recall in children following esophago-gastroduodenoscopy, thus increasing their level of anxiety and reluctance to accept subsequent procedures. Thakkar et al (4), in a cross sectional retrospective study of 10,236 upper GI endoscopic procedures in 0-18 year old children reported an overall immediate complication rate of 2.3%. IV sedation with midazolam, fentanyl, meperidine or ketamine was used in 46% of procedures, whereas 54% procedures were performed under GA. Cardiopulmonary complications were reported in 79.9% of procedures, gastrointestinal complications were reported in 18% of procedures, whereas in 5.9% of procedures complications such as prolonged sedation, drug reaction or rash were reported. All complications were non-fatal and most were hypoxia-related and reversible. They identified a younger age, higher ASA class, female sex and IV sedation as risk factors for developing complications. A complication rate of 1.2% was associated with procedures performed under GA as compared to a 3.7% incidence associated with IV sedation. After adjusting with all other variables, they reported IV sedation to be independently associated with a cardiopulmonary complication rate 5.3% times higher when compared to GA. Agostomi et al (24) reported on complication during sedation for gastroendoscopic procedures in 457 pediatric cases. In their series, complication rate 22% (bradycardia), and 4.4% (hypotension). In a study by Barbi and colleagues (25), major desaturation was noted in 0.7% of all the children, and transient desaturation that resolved spontaneously occurred in 12% of all the procedures. Additionally, the study by Yıldızdas, et al (26) demonstrated that the use of propofol and midazolam/fentanyl in 126 children had 16.6% incidence of respiratory depression as shown by high end-tidal carbon dioxide (>50 mmHg). The high incidence of respiratory depression reflected the better detection of respiratory depression by the use of end-tidal carbon dioxide. In our series 17 complications or side effects were seen totally.

Conclusion

In conclusion our data suggest that deep sedation (with propofol, midazolam, ketamine, fentanyl, or their combination) which managed from anesthesiologist presents advantages in terms of

safety, and depth of sedation. Although our sedation experiences were not complication free, all sedation related complications were transient and easily treated with no permanent sequelae. We recommend deep sedation for pediatric gastroendoscopic procedures applied by anesthesiologists

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

- Lighdale J. Methods of Sedation in Pediatric Endoscopy: A Survey of NASPGHAN Members. *J Pediatr Gastroenterol Nutr* 2007;45:500-502.
- ASGE STANDARDS OF PRACTICE COMMITTEE. Modifications in endoscopic practice for pediatric patients. *Gastrointest Endosc* 2008;67(1):1-9.
- Lighdale J, Mahoney L, Levine P, Heard L, Fox V. Safety of endoscopist versus anesthesiologist administered sedation for pediatric endoscopy: in and outside the operating room. *Gastrointest Endosc* 2006;63:AB94.
- Thakkar K, El-Serag HB, Mattek N, Gilger MA. Complications of pediatric EGD: a 4-year experience in PEDS-CORI. *Gastrointest Endosc* 2007;65:213-221.
- Hoffman GM, Nowakowski R, Troshynski TJ, Berens RJ, Weisman SJ. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model. *Pediatrics* 2002;109:236-243.
- Thompson AM, Wright DJ, Murray W, Ritchie GL, Burton HD, Stonebridge PA. Analysis of 153 deaths after upper gastrointestinal endoscopy: room for improvement? *Surg Endosc* 2004;18:22-25.
- Malviya S, Voepel-Lewis T, Tait AR. Adverse events and risk factors associated with the sedation of children by nonanesthesiologists. *Anesth Analg* 1997;85: 1207-1213.
- Hassall E. Should pediatric gastroenterologists be i.v. drug users? *J Pediatr Gastroenterol Nutr* 1993;16:370-372.
- Becker DE. Pharmacodynamic Considerations for Moderate and Deep Sedation. *Anesth Prog* 2012;59(1):28-42.
- Malviya S, Voepel-Lewis T, Tait AR, Merkel S, Tremper K, Naughton N. Depth of sedation in children undergoing computed tomography: validity and reliability of the University of Michigan Sedation Scale (UMSS). *Br J Anaesth* 2002;88(2):241-245.
- Chung F, Chan V, Ong D. A post-anesthetic discharge scoring system for home readiness after ambulatory surgery. *J Clin Anesth* 1995;7(6):500-506.
- Waring JP, Baron TH, Hirota WK, Goldstein JL, Jacobson BC, Leighton JA, et al. American Society for Gastrointestinal Endoscopy, Standards of Practice Committee. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. *Gastrointest Endosc* 2003;58(3):317-322.
- American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology* 2002;96:1004-1017.
- Fu ES, Downs JB, Schweiger JW, Miguel RV, Smith RA. Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. *Chest* 2004;126(5):1552-1558.
- Vargo JJ, Zuccaro G Jr, Dumot JA, Conwell DL, Morrow JB, Shay SS. Automated graphic assessment of respiratory activity is superior to pulse oximetry and visual assessment for the detection of early respiratory depression during therapeutic upper endoscopy. *Gastrointest Endosc* 2002; 55:826-831.
- Byrne MF, Mitchell RM, Gerke H, Goller S, Stiffler HL, Golioto M, et al. The need for caution with topical anesthesia during endoscopic procedures, as liberal use may result in methemoglobinemia. *J Clin Gastroenterol* 2004;38(3):225-229.
- Amornyotin S, Aanpreung P, Prakarnrattana U, Chalayonnavin W, Chatchawankitkul S, Srikureja, W. Experience of intravenous sedation for pediatric gastrointestinal endoscopy in a large tertiary referral center in a developing country. *Pediatr Anesth* 2009;19:784-791.
- Amornyotin S, Aanpreung P. Clinical effectiveness of an anesthesiologist-administered intravenous sedation outside of the main operating room for pediatric upper gastrointestinal endoscopy in Thailand. *Int J Pediatr* 2010; Article ID 748564, 6 pages.
- Deenadayalu VP, Eid EF, Goff JS, Walker JA, Cohen LB, Heuss LT, et al. Non-anesthesiologist administered propofol sedation for endoscopic procedures: a worldwide safety review. *Gastrointest Endosc* 2008;67:AB107.
- Motas D, McDermott NB, VanSickle T, Friesen RH. Depth of consciousness and deep sedation attained in children as administered by nonanaesthesiologists in a children's hospital. *Paediatr Anaesth* 2004;14:256-260.
- Lighdale JR, Sethna NF, Heard LA, Donovan KM, Fox V. A pilot study of end tidal carbon dioxide monitoring using microstream capnography in children undergoing endoscopy with conscious sedation. *Gastrointest Endosc* 2002;55: AB145.
- Mamula P, Markowitz JE, Neiswender K, Zimmerman A, Wood S, Garofolo MI, et al. Conscious sedation with midazolam and fentanyl for pediatric endoscopy. *Gastrointest Endosc* 2003;57: AB121.
- Levis CR, Walker LS, Barnard JA. Children's knowledge, anticipatory anxiety, procedural distress and recall of esophagogastroduodenoscopy. *J Pediatr Gastroenterol Nutr* 2002;34:68-72.

24. Agostoni M, Fanti L, Gemma M, Pasculli N, Beretta L, Testoni PA. Adverse events during monitored anesthesia care for GI endoscopy: an 8-year experience. *Gastrointest Endosc* 2011;74(2):266-275.
25. Barbi E, Petaros P, Badina L, Pahor T, Giuseppin I, Biasotto E, et al. Deep sedation with propofol for upper gastrointestinal endoscopy in children, administered by specially trained pediatricians: a prospective case series with emphasis on side effects. *Endoscopy* 2006;38(4):368-375.
26. Yıldızdas D, Yapicioglu H, Yilmaz HM. The value of capnography during sedation or sedation/analgesia in pediatric minor procedures. *Pediatr Emerg Care* 2004;20(3):162-165

Relationship between premature ventricular complexes and Neutrophil–Lymphocyte Ratio in asymptomatic healthy young men

Erkan Kibrisli¹, Sinan Iscen^{2*}, Ahmet Yilmaz¹, Salim Ozenc³, Adem Parlak⁴, Duran Tok⁴

Abstract

Background: There is no clear mortality benefit from premature ventricular beat (PVC) suppression in asymptomatic patients. In addition, It has been showed that evidence for structural heart disease consistent with non-ischemic scarring possibly due to inflammation in patients with PVCs. This situation suggests that the mechanisms by which PVCs can be also generated with include clinical and subclinical inflammation. The neutrophil–lymphocyte ratio (NLR) is an easy, cheap, non-invasive, and universally available laboratory marker used to evaluate clinical and subclinical systemic inflammation. We investigated the NLR in asymptomatic healthy young men with PVC (structural heart disease excluded with cardiac magnetic resonance imaging) compared with controls.

Methods: 21 asymptomatic (or atypical complaint) healthy young men with PVCs were recruited into the study as they attended to Diyarbakır Military Hospital for screening from January 2013 to December 2014. The control group consisted of 922 male. Instead of Lown's grading of PVCs, we considered as endpoints > 153 PVC over 24 h (in Holter Electrocardiogram). Data were analysed with the SPSS software version 15.0 for Windows.

Results: There were no significant differences between the 2 groups with respect to age, gender, body mass index, smoking, as well as glucose, creatinine, total cholesterol, triglyceride, LDL-C, HDL-C, haemoglobin levels, white blood cell count, and red cell distribution width. The NLR was significantly higher among the men with PVC than that of the control group (2.6 ± 0.8 vs 2.1 ± 0.7 , respectively; $P = 0.002$).

Conclusions: We found that the NLR is significantly elevated in asymptomatic healthy young men with PVC compared with control group. The increased NLR values might indicate subclinical and clinical inflammation in asymptomatic healthy young men with PVC, and we must consider that there can also be inflammation in the one of the mechanisms of PVCs in humans

Key words: Premature ventricular complexes, neutrophil–lymphocyte ratio, inflammation

Introduction

Premature ventricular complexes (PVC) are a relatively common electrocardiographic abnormality presenting in individuals without overt cardiovascular disease. PVC pathogenesis has traditionally been considered idiopathic and in the absence of severe clinical symptoms or structural cardiac abnormalities, their presence benign (1,2). Recent prospective studies evaluating the prognostic significance of PVC for sudden and total cardiac death in apparently healthy adults directly challenge this view. Among individuals without history of heart disease or stroke, PVC counts independently predicted future cardiac events or sudden cardiac death compared to those without PVC (3-7). But there is no clear mortality benefit from PVC suppression in asymptomatic patients. In addition, It has been showed that evidence for structural heart disease consistent with non-ischemic scarring possibly

due to inflammation in patients with PVCs (8). This situation suggests that the mechanisms by which PVCs can be also generated with include clinical and subclinical inflammation as well as re-entry, enhanced normal or abnormal automaticity, triggered activity resulting in after depolarizations and also mortality benefit can be related to inhibit clinical and subclinical inflammation rather than triggered activity.

The neutrophil–lymphocyte ratio (NLR) is an easy, cheap, non-invasive, and universally available laboratory marker used to evaluate clinical and subclinical systemic inflammation (9,10), and also the NLR is related to the severity of coronary heart disease(CHD) and clinical outcome in patients undergoing angiography and is also related to angiographic progression of coronary atherosclerosis, and it is an independent predictor of adverse outcomes

Received: 11-05-2015, Accepted 28-05-2015, Available Online 01-06-2015

¹Family Physician, Dicle University Medicine Faculty Departments of Family Medicine, Diyarbakır, Turkey

²Cardiologist, Diyarbakır Military Hospital, Diyarbakır, Turkey

³Family Physician, Diyarbakır Military Hospital, Diyarbakır, Turkey

⁴Family Physician, Presidential Guard Regiment, Ankara, Turkey

*Corresponding Author: Sinan Iscen E-mail: dr.iscen@hotmail.com

among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (11,12).

To our knowledge, no study investigated the independent relationship between NLR and PVC in asymptomatic healthy young men. We investigated the NLR in healthy young men with PVC (structural heart disease excluded with cardiac magnetic resonance imaging) compared with controls

Material and method

Subjects: Our study is cross-sectional, retrospective, observational analysis (Military personnel screening). 21 asymptomatic (or atypical complaint) healthy young men with PVCs were recruited into the study as they attended to Diyarbakır Military Hospital for screening from January 2013 to December 2014. Instead of Lown's grading of PVCs, we considered as endpoints > 153 PVC over 24 h (in Holter Electrocardiogram), in that elevated risk for sudden cardiac death was reported for high-risk participants in the Cardiovascular Health Study with > 153 PVC over 24 h, or about 6 events/hr (13). Because Lown's grading of PVCs has become clear over the years that this pertains only to acute myocardial infarction and ischemia and bears no prognostic relevance in other situations. The control group consisted of 922 male. Exclusion criteria were, non-sustained ventricular tachycardia (NSVT), sustained ventricular tachycardia (SVT), structural heart disease (with cardiac magnetic resonance imaging, - Philips, 3.0T), CHD, valvular heart disease, heart failure, hypertension, peripheral arterial disease, diabetes mellitus, renal or hepatic dysfunction, hematological disorders, history of malignancy, acute or chronic infection, and drug use affecting (e.g. alcohol) PVC and NLR.

Blood Sampling: Blood samples were drawn from an antecubital vein by careful after a fasting period of 12 hours. Glucose, creatinine, and lipid profiles were determined by the composition of the sample was calculated in relation to the internal standard using a modification of a commercially available computer program and the results were expressed as mg or mole % and characteristic molar ratios of classes. Hematologic indices were measured within 30 minutes of collecting the blood samples in tubes containing dipotassium EDTA. An automatic blood counter was used for with a Coulter analyser equipped with ZBI counter (Coulter Electronics, Hialeah, Fla).

Echocardiography: All patients were studied by standard Doppler, tissue Doppler, and 2-D echocardiography. All echocardiographic measurements were performed using a commercially available ultrasound system (Philips hd7xe) equipped with a harmonic 4.0-2.5 MHz variable-frequency phased-array transducer. Transthoracic 2-dimensional

echocardiography (TTE) was performed in all study subjects according to the published protocol adopted from the recommendations of the American Society of Echocardiography.

Statistical Analysis:

Data were analyzed with the SPSS software version 15.0 for Windows. Continuous variables from the study groups were reported as mean \pm standard deviation and categorical variables as percentages. To compare continuous variables, the Student t test. Categorical variables were compared using the chi-square test. A two-tailed $P < 0.05$ was considered statistically significant

Results

Clinical and laboratory characteristics of the asymptomatic healthy young men with PVC (structural heart disease excluded with cardiac magnetic resonance imaging) and control group are shown in Table 1. There were no significant differences between the 2 groups with respect to age, gender, body mass index, smoking, as well as glucose, creatinine, total cholesterol, triglyceride, LDL-C, HDL-C, haemoglobin levels, white blood cell count, and red cell distribution width. Neutrophil count was significantly higher among the asymptomatic healthy young men with PVC than that of the control group (4.1 ± 0.6 vs $3.7 \pm 1.1 \times 1000/\text{mm}^3$, respectively; $P = 0.004$). Lymphocyte count was significantly lower among the asymptomatic healthy young men with PVC than that of the control group (1.6 ± 0.45 vs $1.8 \pm 0.51 \times 1000/\text{mm}^3$, respectively; $P = 0.009$).

The NLR was significantly higher among the men with PVC than that of the control group (2.6 ± 0.8 vs 2.1 ± 0.7 , respectively; $P = 0.002$) (Fig. 1).




Figure 1: Comparison of the neutrophil-lymphocyte ratio (NLR) of the Asymptomatic Healthy Young Men with PVC and Control group. The NLR was significantly higher among the men with PVC than that of the control group (2.6 ± 0.8 vs 2.1 ± 0.7 , respectively, $P = 0.002$).

Discussion

Previously it has been showed that evidence for structural heart disease consistent with non-ischemic scarring possibly due to inflammation in patients with premature ventricular beats (PVCs). We found that the NLR, an indicator of inflammation, is significantly elevated in asymptomatic healthy young men with PVC (structural heart disease excluded with cardiac magnetic resonance imaging) when compared with control group.

Since invasive testing is rarely performed in patients with only simple PVCs, there is little information about the mechanisms of PVCs in humans. Information derived from experiments in animals suggests that the mechanisms by which PVCs are generated include: re-entry, enhanced normal or abnormal automaticity, triggered activity resulting in after depolarisations.

Table 1. Comparison of the clinical and Laboratory characteristics of the asymptomatic healthy Young men with PVC and Control group

| | PVC Group n=21 | Control Group n=962 | P |
|---------------------------|----------------------|---------------------------|-------|
| Age | 22.7±2.0 | 22.6±3.1 | 0.16 |
| BMI, kg/m ² | 22.6±1.8 | 22.7±1.7 | 0.91 |
| Echocardiography | normal rmg | normal rmg | |
| Smoking | %14 | 19% | 0.34 |
| Glucose, mg/dl | 97±5 | 90±5 | 0.18 |
| Creatinine, mg/dl | 1.03 ± 0.10 | 1.00±0.22 | 0.06 |
| Total cholesterol, mg/dl | 156±35 | 157 ±24 | 0.28 |
| Triglycerides, mg/dl | 124±69 | 122±36 | 0.19 |
| LDL-C, mg/dl | 102±17 | 101±15 | 0.16 |
| HDL-C, mg/dl | 34±3 | 35±3 | 0.15 |
| WBC, 1000/mm ³ | 6.57±0.92 | 6.58±1.28 | 0.22 |
| Hemoglobin, g/dl | 14.5±1.2 | 14.5±1.1 | 0.15 |
| RDW, % | 14.2±1.2 | 14.3±1.6 | 0.14 |
| Neutrophils, | 4.1±0.6 | 3.7±1.1 | 0.004 |
| Lymphocytes, | 1.6±0.45 | 1.8±0.51 | 0.009 |
| NLR | 2.6±0.8 | 2.1±0.7 | 0.002 |

BMI; body mass index, LDL-C; low-density lipoprotein cholesterol; HDL-C; high-density lipoprotein cholesterol, WBC; white blood cells, RDW; red cell distribution view, NLR; neutrophil-lymphocyte ratio

It has been showed that evidence for structural heart disease consistent with non-ischemic scarring possibly due to inflammation in patients with PVCs (8). However, prophylactic treatment of asymptomatic PVCs in patients without cardiomyopathy has not been shown to improve mortality. This situation suggests that the mechanisms by which PVCs can be also generated with include clinical and subclinical inflammation as well as re-entry, enhanced normal or abnormal automaticity, triggered activity resulting in after depolarisations and also mortality benefit can be related to inhibit clinical and subclinical inflammation rather than triggered activity.

The NLR is easy, cheap, non-invasive, and widely available laboratory marker of systemic clinical and subclinical inflammation. Recently, it gained increased interest due to its role as an independent prognostic factor for many conditions such as uncontrolled hypertension, diabetes mellitus, acute coronary syndromes, valvular heart disease, congenital heart disease, renal or hepatic dysfunction, malignancy, local or systemic infection, and some other inflammatory diseases (14,15).

In our study, the patients with PVC (structural heart disease excluded with cardiac magnetic resonance imaging) and controls were free of CHD. We also excluded non-sustained ventricular tachycardia(NSVT), sustain ventricular tachycardia(SVT), structural heart disease(with cardiac magnetic resonance imaging, - Philips,3.0T), CHD, valvular heart disease, heart failure, hypertension , peripheral arterial disease, diabetes mellitus, renal or hepatic dysfunction, haematological disorders, history of malignancy, acute or chronic infection, and drug use affecting(e.g. alcohol) PVC and NLR.

Limitation

Our study has some limitations. First of it, the number of patients with PVC was small. The second one, our analysis was based on a simple baseline determination at a single time point that may not reflect patient status over long periods.

Conclusion

We found that the NLR is significantly elevated in asymptomatic healthy young men with PVC compared with control group. The increased NLR values might indicate subclinical and clinical inflammation in asymptomatic healthy young men with PVC, and we must consider that there can also be inflammation in the one of the mechanisms of PVCs in humans

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Acknowledgements

This study was designed and analysed by the authors. The database was collected from the Diyarbakır Military Hospital registry by the authors

References

1. Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ, Buckingham TA, Goldberg RJ et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. *N Engl J Med* 1985; 12:193-197.
2. Gaita F, Giustetto C, Di Donna P, Richiardi E, Libero L, Rosa MC et al. Long-term follow-up of right ventricular monomorphic extrasystoles. *J Am Coll Cardiol* 2001; 38:364-370.
3. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Frederiksen BS, Davanlou M et al. Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age. *Am J Cardiol* 2006; 97:1351-57.
4. Cheriath P, He F, Peters I, Li XA, Alagona P, Wu CT et al. Relation of atrial and/or ventricular premature complexes on a two-minute rhythm strip to the risk of sudden cardiac death (the atherosclerosis risk in communities [ARIC] study. *Am J Cardiol* 2011; 107:151-55.
5. Stein PK, Sanghavi D, Sotoodehnia N, Siscovick DS, Gottdiener J. Association of Holter-based measures including T-wave alternans with risk of sudden cardiac death in the community-dwelling elderly: the cardiovascular health study. *J Electrocardiol* 2010; 43:251-59.
6. Abdalla ISH, Prineas RJ, Neaton JD, Jacobs DR et al. Relation between ventricular premature complexes and sudden cardiac death in apparently healthy men. *Am J Cardiol* 1987; 60:1036-42.
7. Raiha IJ, Piha SJ, Seppanen A, Puukka P, Sourander L. Predictive value of continuous ambulatory electrocardiographic monitoring in elderly people. *Br Med J* 1994; 309:1263-67.
8. Jeserich M, Friedrich MG, Olschewski M, Kirchberger J, Kimmel S, Bode C et al. Evidence for non-ischemic scarring in patients with ventricular ectopy. *Int J Cardiol*. 2011;147:482-84.
9. Arbel Y, Finkelstein A, Halkin A, Birati EY, Revivo M, Zuzut M et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography *Atherosclerosis*. 2012;225:456-60.
10. Kaya MG. Inflammation and coronary artery disease: as a new biomarker neutrophil/lymphocyte ratio [in Turkish]. *Turk Kardiyol Dern Ars*. 2013;41(3):191-192.
11. Kaya MG, Akpek M, Lam YY, Yarlioglu M, Celik T, Gunebakmaz O, et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. *Int J Cardiol*. 2013 168(2):1154-9
12. Kalay N, Dogdu O, Koc F, Yarlioglu M, Ardic I, Akpek M, et al. Hematologic parameters and angiographic progression of coronary atherosclerosis. *Angiology*. 2012; 63(3):213-217.
13. Stein PK, Barzilay JI, Chaves PHM, Mistretta SQ, Domitrovich PP, Gottdiener JS, et al. Novel measures of heart rate variability predict cardiovascular mortality in older adults independent of traditional cardiovascular risk factors: the cardiovascular health study (CHS). *J Cardio Electrophysiol* 2008, 19:1169-74.
14. Balta S, Demirkol S, Cakar M, Arslan Z, Unlu M, Celik T. Other inflammatory markers should not be forgotten when assessing the neutrophil-to-lymphocyte ratio [published online April 23]. *Clin Appl Thromb Hemost*. 2013. 19(6):693-4.
15. Sahin DY, Elbasan Z, Gür M, Yildiz A, Akpınar O, İcen YK, et al. Neutrophil to lymphocyte ratio is associated with the severity of coronary artery disease in patients with ST-segment elevation myocardial infarction. *Angiology*. 2012. 64(6):423-9

Delayed organophosphate induced polyneuropathy

Abuzer Coskun¹, Afsin Emre Kayipmaz^{2*}, Sedat Ozbay¹, Osman Mahir Okur¹,
Ilham Ozkan¹, Sevki Hakan Eren³

Abstract

Intoxication with organophosphate compounds used for pest control is common in Turkey. Organophosphate intoxication may occur during agricultural spraying, transport of organophosphate compounds, or domestic accidents, although suicide attempts are the most common way of intoxication. In this case, we present a 23-year-old woman ingested a fistful of painkillers and drank a sip of unknown syrup after having a quarrel with her family. About 18 days after drug intoxication she began noticing headache and weakness and numbness in her arms and legs. A detailed patient history taken in the emergency department indicated that the syrup she had taken for suicidal purpose was an organophosphate compound. An organophosphate –induced polyneuropathy was primarily considered. In conclusion, organophosphate intoxication should always be remembered in the differential diagnosis of intoxication cases even when no specific compound could be determined.

Keywords: Late onset, organophosphate poisoning, polyneuropathy.

Key words: Late onset, organophosphate poisoning, polyneuropathy

Introduction

Intoxication with organophosphate compounds used for pest control is common in Turkey (1). Organophosphate intoxication may occur during agricultural spraying, transport of organophosphate compounds, or domestic accidents, although suicide attempts are the most common way of intoxication (2, 3). Organophosphate intoxication may occur via oral, respiratory, transdermal, or parenteral route (4).

Organophosphates irreversibly bind to acetylcholine receptors to inhibit acetylcholine breakdown at neuromuscular junction. As a result, acetylcholine receptors are continually stimulated, leading to cholinergic, nicotinic, and central nervous system signs and symptoms (4).

The clinical picture depends on the type, dose, and route of administration of the culprit compound. Death typically occurs within the first 24 hours, usually due to respiratory failure (3). Some complications of organophosphate intoxication have been reported, including “delayed organophosphate - induced polyneuropathy” that has been only rarely reported (2).

It usually arises 14-18 days after intoxication (2, 4). This paper discusses a rare case of delayed organophosphate - induced polyneuropathy

Case

A 23-year-old woman ingested a fistful of painkillers and drank a sip of unknown syrup after having a quarrel with her family. Four hours later, she had been taken to a nearby hospital with nausea, vomiting, and abdominal pain, where she had been treated for drug intoxication at an intensive care unit for 2 days and discharged uneventfully. About 18 days after drug intoxication she began noticing headache and weakness and numbness in her arms and legs. Her symptoms progressively deteriorated over 2 days and she was admitted to our emergency department with inability to walk.

On admission, her general status was well and she was conscious. Her blood pressure was 100/70 mmHg, pulse rate 86 beats per minute (bpm), respiratory rate 18/minute, and body temperature 36.7°C. Her head and neck examination revealed no abnormality. She had normal respiratory sounds and no rales or ronchi on auscultation. Heart sounds were also normal, with no additional sounds or murmurs. Her abdomen was non-tender and there was no mass lesion on palpation.

Neurological examination revealed mild weakness in both upper extremities; both lower extremities had a 3/5 muscular weakness, reduced deep tendon reflexes, and minimal sensory loss.

Received: 01-04-2015, Accepted 22-04-2015, Available Online 01-06-2015

¹Numune Hospital, Department of Emergency, Sivas-Turkey

²Baskent University Faculty of Medicine, Department of Emergency, Ankara-Turkey

³Cumhuriyet University Faculty of Medicine, Department of Emergency, Sivas-Turkey

*Corresponding Author: Afsin Emre Kayipmaz E-mail: akayipmaz@baskent.edu.tr

Table 1: Important blood parameters of delayed organophosphate induced polyneuropathy patient

| | Value | Normal range |
|-------------------------------------|-----------------|--------------------------|
| Hemoglobin | 12.4 g/dl | (12-16 g/dl) |
| White Blood Cell (WBC) | 13400/ μ l | (4500-11000/ μ l), |
| Platelet | 242000/ μ l | (150000–400000/ μ l) |
| Glucose | 162 mg/dl | (70-105 mg/dL) |
| Blood Urea Nitrogen (BUN) | 17 mg/dl | (6-21 mg/dl) |
| Creatinine | 1.1 mg/dl | (0.5-1.3 mg/dl) |
| Alanine transaminase (ALT) | 46 U/l | (0-31 U/l) |
| Aspartate transaminase (AST): | 47 IU/l | (0-31 IU/l) |
| Creatine kinase (CK) | 152 IU/l | (22-192 IU/l) |
| Creatin kinase muscle-brain (CK-MB) | 41 IU/l | (0-25 IU/l) |
| Pseudocholinesterase | 2450 U/l | (5400-13200 U/l) |

Electrocardiogram (ECG) of patient showed a normal sinus rhythm with a rate of 76 bpm and laboratory examinations were as in Table 1.

A detailed patient history taken in the emergency department indicated that the syrup she had taken for suicidal purpose was an organophosphate compound. An organophosphate – induced polyneuropathy was primarily considered and a neurology consultation was requested with the working diagnosis of delayed organophosphate - induced polyneuropathy. Distinction between acute vs chronic organophosphate intoxication was based on patient history.

The consulting department admitted the patient to hospital and performed an electromyography (EMG), which revealed sensorimotor neuropathy consistent with “delayed organophosphate -induced polyneuropathy“. MR examinations revealed no pathology.

The patient was put on steroid therapy and discharged after resolution of much of her symptoms

Discussion

Organophosphates are chemical compounds that are commonly used for pest control in agriculture. Their wide availability and ease of access may sometimes lead to accidental or suicidal ingestions (3). Suicidal ingestions most commonly occur via oral route although parenteral route has also been reported (5).

Pesticide-induced intoxications are common in Turkey. According to 2008 statistics of the National Poison Center of Turkey (NPCT), intoxications caused by agricultural compounds ranked second among all intoxication events, with a rate of 8.34%. Among pesticide intoxications, those occurring with organophosphates rank first.

According to reports, 47.66% of all pesticide intoxications were caused by insecticides and %20.98 of them were secondary to organophosphate compounds (1).

Organophosphates act by inhibiting the cholinesterase enzyme found at nerve endings. Symptoms and course of intoxication depend on the type, amount, and route of ingestion of the culprit compound.

In acute intoxication, majority of cases become symptomatic within first 8 hours while others begin experiencing symptoms within 24 hours (4). Three stages of organophosphate intoxication have been defined. These include the acute cholinergic crisis, the intermediate syndrome, and delayed polyneuropathy (6). Death usually occurs during acute cholinergic crisis or the intermediate syndrome (2).

Acute cholinergic crisis is characterized by muscarinic, nicotinic, and central nervous system signs and symptoms, including weakness, nausea, vomiting, myosis, salivation, altered consciousness, respiratory difficulty, muscle fasciculation's, and bradycardia (2, 4).

The intermediate syndrome usually spans from the first to fourth day of intoxication and is characterized by paralysis of respiratory, cranial, flexor neck and proximal limb muscles. It may culminate into death when it involves respiratory muscles (4).

Delayed organophosphate induced polyneuropathy is typically encountered between 14th and 28th days of intoxication (2, 4). It has been linked to suppression of neuropathy target esterase (NTE) by organophosphates in the nervous tissue (2).

Many lipid-soluble organophosphates may cause delayed polyneuropathy with no signs and symptoms of acute poisoning (4). There is loss of function in the ascending and descending limbs of spinal cord as well as sensory and motor axons of peripheral nerves.

The acute stages of organophosphate-induced polyneuropathy are characterized by leg cramps. This is followed by sensory loss and muscle weakness in legs. Weakness becomes advanced and widespread and deep tendon reflexes become suppressed in later stages (2, 4).

As for the prognosis of polyneuropathy, some functions may be regained over time although some severe cases may have residual sequela, including ataxia, drop foot, and spasticity (7).

This syndrome usually mimics Guillain-Barre syndrome (4). Our patient also had bilateral muscle weakness and sensory loss. Most of the symptoms of our case disappeared by the time of discharge. Many cases with appropriate therapy at the acute intoxication stage may avoid the last stage of the intoxication (2, 4).

Our patient, unfortunately, was not managed appropriately at the acute stage and she was thus at risk of this complication. Delayed organophosphate - induced polyneuropathy has no proven therapy although one study indicated that B complex vitamins and prednisolone may be of some benefit (8). Hence, our case enjoyed a resolution of her symptoms after steroid therapy.

Parkinsonism as a result of basal ganglion injury is another neurological manifestation of organophosphate intoxication. Shahar et al reported a 15-year-old male with extra pyramidal symptoms such as poker face, rest tremor, inability to wink, cogwheel rigidity, and slow walking. He responded to amantadine treatment and his symptoms completely disappeared by 7 days (9).

Organophosphate intoxication is usually diagnosed by history, clinical signs and symptoms, and laboratory test (4). Package of the ingested compound should be inspected to determine the responsible molecule whenever possible (6).

The characteristic garlic-like smell of these compounds may sometimes warn physician. Cholinergic signs and symptoms also help in the diagnostic process. Myosis is the most common sign. The prognostic role of plasma and erythrocyte cholinesterase level measurements is low and does not predict the amount of the antidote or need for ventilatory support. Routine laboratory tests also have limited diagnostic role (4).

Some patients may exhibit signs of pulmonary edema or acute respiratory distress syndrome (ARDS) on chest X-Ray (8). In our case no cholinesterase level measurement had been done at the outside center since she had not been considered to suffer from organophosphate intoxication. Treatment of organophosphate intoxication consists of decontamination, airway control, gastric lavage, and administration of antidotes, atropin and pralidoxime (4). As our patient applied at a later stage, these therapies were not applied.

Karasu et al reported a 29-year-old woman with sub-acute neuropathy 3 weeks after organophosphate ingestion. The authors suggested that organophosphate intoxication should be considered in the differential diagnosis of unilateral distal neuropathy (10). Gulle et al published a 13-year-old

male child with polyneuropathy 3 weeks after organophosphate intoxication (11).

Conclusion

In intoxication cases, package of the ingested compound should be inspected to determine the culprit molecule whenever possible.

Organophosphate intoxication should always be remembered in the differential diagnosis of intoxication cases even when no specific compound could be determined since suicidal attempts with agricultural pesticide compounds are common in Turkey.

Early diagnosis and therapy of the deadly organophosphate intoxication may avoid much of the complications and sequel in the long term

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This study was presented as poster presentation at the 10th National Emergency Medicine Congress and the 1st Intercontinental Emergency Medicine Congress, 15-18 May 2014, Antalya, Turkey.

References

- Ozcan N, Ikinciogullari D. Ulusal Zehir Danisirma Merkezi 2008 Yili Calisma Raporu Ozeti. Turk Hij Den Biyol Derg. 2009; 66: 29-58.
- Karalliedde L. Organophosphorus poisoning and anaesthesia. *Anaesthesia*.1999; 54: 1073-88.
- Yurumez Y, Durukan P, Yavuz Y, Ikizceli I, Avsarogullari L, Ozkan S, et al. Acute organophosphate poisoning in university hospital emergency room patients. *Intern Med*. 2007; 46: 965-9.
- Robey CW, Meggs WJ, section 15: Toxicology, chapter 195: Pesticides. Tintinalli JE, Stapczynski JS, Cline
- MD, Ma JO, Cydulka RK, Merckler GD. *Tintinalli's Emergency Medicine 7th New York: McGraw-Hill CO 2010: 15: 1297-305.*
- Malla G, Basnet B, Vohra R, Lohani SP, Yadav A, Dhungana V. Parenteral organophosphorus poisoning in a rural emergency department: a case report. *BMC Res Notes*. 2013; 6: 524.
- Kozaci N, Acikalin AA, Satar S, Icme F. Causes of death and treatment of organophosphorus pesticide poisoning. *JAEM*.2012; 11: 176-82.
- Singh S, Sharma N. Neurological syndromes following organophosphate poisoning. *Neurol India*.2000; 48: 308-13.
- Kass R, Kochar G, Lippman M. Adult respiratory distress syndrome from organophosphate poisoning. *Am J Emerg Med*. 1991; 9: 32-3.

10. Shahar E, Bentur Y, Bar-Joseph G, Cahana A, Hershman E. Extrapramidal parkinsonism complicating acute organophosphate insecticide poisoning. *Pediatr Neurol.* 2005; 33:378-82
11. Karasu M, Baransel IA, Ozdil S, Dulger HE. Sub acute periphheric neuropathy after organophosphate poisoning (Chlorpyrifos-diethyl): A case report. *JAEM.* 2007; 5: 37-8.
12. Gulle S, Agin H, Asilsoy S, Atlihan F, Bak M, Genel F, et al. Two serious complications of organophosphate poisoning in the same patient: Acute pancreatitis and late-onset polyneuropathy: case report. *Turkiye Klinikleri J Pediatr* 2010; 19:62-5.

Treatment of postoperative atelectasis with dornase alpha (Pulmozyme®) after congenital heart surgery

Mustafa Hakan Zor¹, Abdullah Ozer^{1*}, Huseyin Demirtas¹, Yigit Kilic¹, Baris Mardin¹

Abstract

One year old patient followed with tetralogy of fallot (TOF) was admitted to our service for surgical repair. Ventricular septal defect (VSD) was repaired with a Dacron patch. The infundibular muscle was resected to allow for unobstructed flow of blood to the pulmonary valve and the area above the pulmonary valve was opened with a polytetrafluoroethylene (PTFE) patch. The patient was intubated three times because of the atelectasis occurred in the lungs after the surgery. Atelectasis was treated with nebulised dornase alpha. It avoided the recurrence of atelectasis and the patient was discharged

Key words: Atelectasis, Dornase Alpha (Pulmozyme), Congenital Heart Surgery

Introduction

The prevalence of congenital heart disease (CHD) is between 8 and 10 children per 1000 live births. The average number of cardiovascular surgeries for CHD that are necessary in Brazil is of the order of 23,077 procedures per year, including newborn babies with CHD and cases requiring reoperations (1). Pulmonary complications of postoperative pediatric cardiac surgery observed in the study of Felcar et al. where: atelectasis, pneumonia, pleural effusion, pneumothorax, chylothorax, pulmonary hypertension, pulmonary haemorrhage and diaphragmatic paralysis, whereas the first two aforementioned complications are the more common ones (2). Atelectasis, defined as collapse of a certain region of the lung parenchyma (3) is the most common complication in the postoperative period of cardiac surgery (4) by worsening oxygenation, decreasing pulmonary compliance, leading to inhibition of cough and pulmonary clearance and may lead to respiratory failure and increase pulmonary vascular resistance. Heart surgeries associated with CPB have as adverse effect the increased capillary permeability that causes edema, which results in decreased lung compliance and gas exchange (6), in addition to lead to airway obstruction, atelectasis, decreased functional residual capacity and, therefore, hypoxemia (5). Pulmonary complications are the most common causes of morbidity and mortality in the postoperative period after congenital heart surgery. Both mechanical and gas exchange abnormalities result in increased ventilator requirements, intensive care unit (ICU) stay and mortality.

Parenchymal lung disease can be caused by a variety of conditions including nosocomial pneumonia, atelectasis and use of cardiopulmonary bypass. Direct surgical trauma to the respiratory system can result in diaphragmatic paralysis, chylothorax, subglottic stenosis or vocal cord paralysis. Disturbances in the pulmonary vasculature can also trigger complications including pulmonary embolism, plastic bronchitis and even pulmonary hypertensive crises in certain at risk populations (7).

Case

One year old female patient followed with tetralogy of fallot (TOF) was admitted to our service for surgical repair. Her weight was eight kilograms. She was diagnosed with TOF in utero by fetal echocardiography at 27 weeks of gestation. After birth her echocardiography and cardiac catheterization findings were intact Interatrial septum, sub aortic ventricular septal defect, dextroposed aorta, right ventricular hypertrophy, hypo-plastic pulmonary artery and dilated ascending aorta. Total correction of TOF was decided. VSD was repaired with a Dacron patch. The infundibular muscle was resected to allow for unobstructed flow of blood to the pulmonary valve and the area above the pulmonary valve was opened with a PTFE patch. On the first postoperative day when she met extubation criteria she was extubated. 6 hours after extubation she had difficulty in breathing. Her arterial blood gas was analysed. She had respiratory acidosis and she was re-entubated.

Received: 08-04-2015, Accepted 27-04-2015, Available Online 01-06-2015

¹Gazi University Faculty of Medicine, Department of Cardiovascular Surgery, Ankara, Turkey

*Corresponding Author: Abdullah Ozer E-mail: dr-abdozer@hotmail.com



Figure 1: Postoperative day 1, chest x-ray with total atelectasis of the right lung. The patient was intubated



Figure 4: Postoperative day 4, atelectasis of the right lung recovered and then the patient was ex-tubated



Figure 2: Postoperative day 2, atelectasis of the right lung recovered and then the patient was ex-tubated.




Figure 5 - Postoperative day 5



Figure 3: Postoperative day 3, partial collapse of the right lung (recurrent atelectasis) the patient was re-entubated. Pulmozyme treatment was started.



Figure 6 - Postoperative day 6

The chest x ray showed total atelectasis of the right lung. After 17 hours of intubation the atelectasis of the right lung totally recovered on chest x ray. The patient was extubated again. Pulmonary rehabilitation techniques and bronchodilators were used for the treatment of atelectasis. After nine hours she had difficulty in breathing again. She had bradycardia, her oxygen saturation level was at 50% and she was intubated again.

Her chest x ray showed total atelectasis of the right lung. After 15 hours she was extubated again. We started to treat the patient with nebulised Dornase alpha (Pulmozyme®) twice a day. Pulmozyme is a recombinant human deoxyribonuclease I (rhDNase) an enzyme which selectively cleaves DNA. Each ampule has 2.5 mL of the solution. Each mL of aqueous solution contains 1 mg dornase alfa. After administration of 2.5 mg of Dornase alpha twice a day for three days the atelectasis of the right lung started to recover. The patient was discharged from the Intensive Care Unit (ICU) and was followed in the clinic. She was treated with Dornase alpha for three more days in the clinic and then on the fifth day she was discharged from the hospital.

Discussion

Atelectasis resolves with the use of non-invasive mechanical ventilation but after the extubation, by the effect of the spontaneous breathing, lung starts to collapse. Postoperative pain management is important in patients who undergo open heart surgery and aorta surgery. The use of opioid-based analgesics for pain control after cardiac surgery is inevitable. Poorly controlled pain also contributes to hemodynamic instability (8). In fact, several authors have reported that a continuous positive airway pressure, with or without intermittent positive pressure ventilation, alleviates a tracheal collapse (9,10).

Pulmozyme is a nebulised form of recombinant human DNase I (rhDNase). It is reliable, non-invasive and FDA approved. Recombinant human DNase I (rhDNase) has been shown to depolymerise DNA and thereby reduce the in vitro viscoelasticity of sputum in patients with cystic fibrosis and improved pulmonary function in patients with cystic fibrosis (CF) (11).

Its efficacy has been well documented in cystic fibrosis, whereas case reports have described a beneficial effect in other respiratory disorders. Recombinant human DNase I (rhDNase, Pulmozyme, dornase alpha) has been approved for the management of CF (12,13).

Conclusion

In conclusion, nebulised form of Dornase Alpha (Pulmozyme®) has a positive effect on morbidity and mortality in patients with atelectasis that do not resolve due to pulmonary medication and rehabilitation program after congenital heart surgery

Conflict of Interest: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

1. Pinto Jr VC, Daher CV, Sallum FS, Janete MB, Croti UA. Situação das cirurgias cardíacas congênitas no Brasil. *Rev Bras Cir Cardiovascular*. 2004; 19(2): 3-4
2. Felcar JM, Guitti JCS, Marson AC, Cardoso JR. Fisioterapiapré-operatória na prevenção das complicações pulmonares em cirurgia cardíaca pediátrica. *Rev Bras Cir Cardiovasc*. 2008; 23(3):383-8.
3. Andrejaitiene J, Sirvinskas E, Bolys R. The influence of cardiopulmonary bypass on respiratory dysfunction in early postoperative period. *Medicina (Kaunas)*. 2004; 40(Suppl1):7-12.
4. Kavanagh BP. Perioperative atelectasis. *Minerva Anesthesiol*. 2008; 74(6):285-7.
5. Udem-Sternberg BS, Petak F, Saudan S, Pellegrini M, Erb TO, Habre W. Effect of cardiopulmonary bypass and aortic clamping on functional residual capacity and ventilation distribution in children. *J Thorac Cardiovasc Surg*. 2007; 134(5): 1193-8.
6. Nina RVAH, Gama MEA, Santos AM, Nina VJS, Figueiredo NETO JA, Mendes VGG, et al. O escore de risco ajustado para cirurgia em cardiopatias congênitas (RACHS-1) pode ser aplicado em nosso meio? *Rev Bras Cir Cardiovasc*. 2007; 22(4): 425-31.
7. Healy, Fiona; D. Hanna, Brian; Zinman, Raetzelle *Current Respiratory Medicine Reviews*, Volume 7, Number 2, April 2011, pp. 78-86(9 Bentham Science Publishers
8. Lee A. Fleisher. *Anesthesia and uncommon disease*. Elsevier Health Sciences, 2012; Sixth Ed. pp (6-7)
9. Oh AY, Kim YH, Kim BK, Kim HS, Kim CS Unexpected tracheomalacia in Marfan syndrome during general anesthesia for correction of scoliosis. *Anesth Analg* 2002; 95: 331-2.
10. Kanter RK, Pollack MM, Wright WW, et al. Treatment of severe tracheobronchomalacia with continuous positive airway pressure (CPAP). *Anesthesiology* 1982; 57: 54-6.
11. Shah PL, Scott SF, Knight RA, et al. In vivo effect of rhDNase on sputum in patients with cystic fibrosis. *Thorax* 1996;51(2):119-25.
12. Hassan NO, Chess PR. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. *Pediatrics* 2001;108:468.

Cyst hydatid case ruptured after awake intubation causing difficult airway

Nureddin Yuzkat^{1*}, Muhammed Bilal Cegin²

Abstract

Encountered throughout the history, the Cyst Hydatid is a parasitary disease caused by Echinococcus Granulosus. Cyst hydatid settles in the liver almost at a rate of 60% and about 30% in the lungs. The cysts settling in the lungs are generally solitary and asymptomatic. While the cyst hydatid of the lungs is often seen as solitary, the perforation rate occurring spontaneously in these cases was reported as 0.36%. The iatrogenic perforation is quite rare, like 1% in the studies. In the literature, we could not come across a cyst hydatid case ruptured due to intubation. In this article, we aimed to present a cyst hydatid case that was operated on due to diaphragmatic hernia, instantly getting ruptured after intubation and causing a difficult airway.

Key words: intubation, cyst hydatid, difficult airway, ruptures late onset,

Introduction

Encountered throughout the history, the cyst hydatid is a parasitary disease caused by Echinococcus Granulosus. Its prevalence in Turkey is presumed to be around 50 per 100 thousand (1). Cyst hydatid settles in the liver almost at a rate of 60% and about 30% in the lungs. The cysts settling in the lungs are generally solitary and asymptomatic (2). However, it provides findings in some patients with a symptom or a perforation due to pressure. Perforations may be usually spontaneous or iatrogenic (traumatic, surgical) (3, 4).

In the literature, we could not come across a cyst hydatid case ruptured due to intubation. In this article, we aimed to present a cyst hydatid case that was operated on due to diaphragmatic hernia, instantly getting ruptured after intubation and causing a difficult airway

Case

A 64kg -male patient aged 78 and planned to be taken under operation due to his right diaphragmatic hernia was preoperatively evaluated. His physical examination and laboratory parameters were normal. In his thorax CT, a 72x58mm thick-walled cavitory lesion containing a solid component in the apical upper lobe of the left lung was monitored (Figure 1). The case was taken under operation without performing a premedication. In the operating room, a routine anesthesia monitorization was performed.

His blood pressure was measured as 145/79mmHg, whereas his heart rate was 85 beats/minute and the oxygen saturation was 94%. Then 0.9% fluid was placed through a vascular access. After administering 1mg- iv midazolam to the case, an anesthetic induction with 2.5µg/kg fentanyl, 2mg/kg propofol and 0.6mg/kg rocuronium was performed. An endotracheal intubation with a 37F left-sided double-lumen tube was performed, as well, and the tube level was verified. After observing that both lungs were normally ventilated, the case was strapped to a mechanical ventilator. When the case was given a right-side position for the surgery, first a pressure increase in the mechanical ventilator and then an insufficient tidal volume was noticed.

The pressure was immediately brought under control by performing manual respiration to the case. It was seen that there was a severe resistance in the airways. The left lung sounds/beats could not be received by merely listening. The case had a ventilation problem. The peripheral oxygen saturations dropped down to 72%, whereas the blood pressure went down to 84/50mmHg. The case was given a supine position, an aspiration in tube was performed, and an intraoperative chest radiography (X-ray) was taken. (Figure 2). The left lung was determined to have been totally closed. Then an aspiration with a physiological saline solution was performed once again. A large amount of serous fluid was aspirated. The peripheral oxygen saturations rose up to 92%.




Figure 1: In his thorax CT, a 72x58mm thick-walled cavity lesion containing a solid component in the apical upper lobe of the left lung

It was understood that the cyst hydatid in left lung was ruptured. The case was administered with both an intravenous fluid replacement and intravenous 80mg methylprednisolone (Prednol-L, Mustafa Nevzat, Turkey) along with 40mg pheniramine maleate (Avil, Sandoz, Turkey) for anaphylaxis prophylaxis. A diagnostic bronchoscopy was performed on the patient, and the cyst content was aspirated. The surgery was postponed to be performed under elective conditions. The case was brought to the intensive care unit in intubation. The case received a mechanical ventilation support for 24 hours as well as an inotropic support treatment for 48 hours since the course of the process was hypotensive. He was then referred to the 3rd day-service department after his clinical picture and hemodynamics recovered.

Discussion

Cyst hydatid is a parasitosis capable of arresting all the organs, notably the liver most frequently. It may occur in any organ, such as the lungs, kidneys, bile ducts, mesentery, brain and the soft tissue (5). It is a health issue still seen in Turkey. The incidence of cyst hydatid in the Turkish society is reported as 1/2000 (6). People contract this disease primarily by getting in contact with the dogs carrying the disease or by consuming contaminated foods. The most affected organs are the liver and the lungs (7).

While the cyst hydatid of the lungs is often seen as solitary, the perforation rate occurring spontaneously in these cases was reported as 0.36%. The iatrogenic perforation is quite rare, like 1% in the studies (4,8).



Figure 2: intraoperative chest X-ray radiography

Gunay et al. (9) report that only one out of 16 cyst hydatid cases they treated due to a traumatic rupture in 12 years was settled in the lungs. Şahin et al. (10), on the other hand, stated that in only one case out of 80 cyst hydatid cases had a rupture due to a blunt trauma been determined.

The case we have presented was taken under operation due to diaphragmatic hernia, and right after the intubation was the cyst in the left lung perforated. No surgery had been performed on the case, nor was an interventional action except for the intubation done. For this reason, we are of the opinion that the cyst was spontaneously perforated.

In the literature, perforated cyst hydatid cases seen under anesthesia were reported (7). Yet, no spontaneous perforation associated with intubation was encountered. Apart from this, the point to be taken into consideration in the first place in the cases in which the cyst is perforated is the possibility of the development of anaphylaxis.

When the cyst is perforated, the cyst fluid of high antigenic characteristic permeates into the blood circulation, and anaphylaxis may occur as the result of histamine release (7). In perforated cases, it is advised that anaphylaxis prophylaxis be performed, and measures be taken to protect hemodynamics (1).

In our case, following the consideration on perforation, the anaphylaxis prophylaxis was practised, and a fluid treatment for protecting the blood pressure was performed. However, a hypotension developed in the case in question, and thus, an inotropic support was given in the intensive care unit.

Conclusion

In conclusion, cyst hydatid may be spontaneously perforated in the patients in intubation during unexpected moments. Therefore, we wished to emphasize the fact that cyst hydatid is a serious parasitosis likely to cause difficult airways and anaphylaxis

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This study was accepted as a poster presentation in 20th International Intensive Care Symposium - ICISTANBUL 2015, May 8-9, 2015, Istanbul, Turkey.

References

1. Kocuturk O, Guruz Y, Akay H, et al. Toraks derneği paraziter akciğer hastalıkları tanı ve tedavi rehberi 2002. *Toraks* 2002; 3:1-16.
2. Meteroglu F, Isik AF, Elbeyli L. Complicated diaphragmatic cyst hydatid having difficulty in diagnosis: two cases. *Dicle Med J* 2010; 37:294-296.
3. Yuncu G, Sevinc S. Akciğer hidatik kistleri. In: Ökten İ, Güngör A, editör. *Göğüs Cerrahisi*. Ankara: Sim Matbaacılık; 2003. p.1011-24
4. Kabiri EH, El Maslout A, Benosman A. Thoracic rupture of hepatic hydatidosis (123 cases). *Ann Thorac Surg* 2001;72:1883-1886.
5. Oguz A, Gumus M, Turkoglu A, Goya C, Alabalik U, Boyuk A. Hydatid disease localized in mesorectum: Case report. *J Clin Exp Invest* 2015; 6:75-77.
6. Sahin E, Enon S, Cangir AK, et al. Single-stage transthoracic approach for right lung and liver hydatid disease. *J Thorac Cardiovasc Surg* 2003;126:769-73.
7. Goktas U, Yuzkat N, Isik Y, Cegin MB, Avsar A. The efficacy of prophylaxis for anaphylaxis in cyst hydatid surgery. *Eastern Journal of Medicine* 2014;19:58-60.
8. Balcı AE, Eren N, Eren S, Ulku R. Ruptured hydatid cysts of the lung in children: clinical review and results of surgery. *Ann Thorac Surg* 2002;74:889-892.
9. Gunay K, Taviloglu K, Berber E, Ertekin C. Traumatic rupture of hydatid cysts: a 12-year experience from an endemic region. *J Trauma* 1999;46:164-167.
10. Sahin E, Kaptanoglu M, Nadir A, Ceran C. Traumatic rupture of a pulmonary hydatid cyst: a case report. *Ulus Travma Derg* 2006;12:71-75.



MEDICAL SCIENCE & DISCOVERY



ISSN: 2148-6832

Publisher LuLu Press, USA



Sponsored by



SAGLIK GERECLERI TICARET A.S.

Medical equipments trade co.

www.tutkusaglik.com

International Journal of
Medical Science and Discovery
Open Access Scientific Journal
August 2015, Vol.2, No.4

ISBN 978-1-329-18736-8

90000



9 781329 187368

www.medscidiscovery.com